Quantitative proteome analysis of S-nitrosylation on synaptosomal proteins in Alzheimer's disease by Wijasa, Teodora Stella
  
 
Quantitative proteome analysis 
of S-nitrosylation on synaptosomal proteins 
in Alzheimer’s disease 
 
 
Dissertation 
 
 
For degree of achievement 
Doctor of Natural Science (PhD) 
Doktor der Naturwissenschaften (Dr. rer. nat) 
 
Faculty of Mathematics and Natural Sciences 
Rheinische Friedrich-Wilhelms-Universität Bonn 
 
 
 
by 
Teodora Stella Wijasa, M.D., M.Sc. 
from 
Jakarta, Indonesia 
 
Bonn 2018 
 
 
 
 
  ii 
Supervisors 
 
Prof. Dr. Michael T. Heneka 
Department of Neurodegenerative Diseases & Geropsychiatry 
Uniklinikum Bonn 
 
Prof. Dr. Walter Witke  
Institute of Genetics  
University of Bonn, Faculty of Biology 
 
Prof. Dr. Volkmar Gieselmann 
Institute of Biochemistry and Molecular Biology 
University of Bonn 
 
Prof. Dr. Sabine Tröger 
Institute of Geography, Developmental Geography 
University of Bonn 
 
 
 
 
 
 
Date of the defense  
26 April 2019 
 
Year of publication  
2019 
 
 
 
  iii 
Abstract 
Alzheimer’s disease (AD) is an irreversible, progressive and most common type 
of dementia in the aging population. AD pathophysiology starts slowly and deteriorates 
over time before the clinical diagnosis of dementia can be made. Neuropathologic 
features of AD are the presence of amyloid deposits, neurofibrillary tangles, synapse 
loss and neurodegeneration. Increasing evidence proposes neuroinflammation as one 
of the essential components of AD pathogenesis. Numerous studies have shown the 
involvement of protein s-nitrosylation in the development of AD pathology. The current 
study targeted s-nitrosylation in synaptosomal proteins, which have been isolated from 
mouse and human brain tissues using an isobaric mass tag (iodoTMT) method and 
nanocapillary high performance liquid chromatography tandem mass spectrometry 
(nanoHPLC MS/MS). Mice samples were collected and analyzed according to their 
age (3-months and 12-month-old mice) and genotype (APP/PS1 and NOS2 knockout 
on 12-month-old mice) effects. Data obtained from murine AD models were then 
compared to brain samples from Alzheimer’s disease, mild cognitive impairment (MCI) 
and healthy elderly subjects. The results represent a candidate list of s-nitrosylated 
synaptic proteins isolated from mouse and human samples, which could be further 
evaluated as early biomarkers in AD. In addition, the iodoTMT method has been 
confirmed for the analyzation of S-nitrosylation instable protein modifications, 
particularly in studies with finite sample materials.  
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1. Introduction 
1.1. General Introduction 
Alzheimer’s disease is an irreversible, progressive and most common type of 
dementia in the aging population (Crous-Bou et al., 2017). The disease is named after 
the German psychiatrist and neuropathologist Dr. Alois Alzheimer. In 1906, Dr. 
Alzheimer described the case of his 51-year-old patient Auguste Deter (Hippius, 
2003). In the period of 5 years she developed progressive cognitive impairment, 
impaired social functioning, delusions, and hallucinations. In her brain autopsy, Dr. 
Alzheimer examined many abnormal clumps (now known as amyloid deposits) and 
tangled bundles of fibers (now known as neurofibrillary tangles) (Graeber and Möller, 
1998; Hippius, 2003).  
 
The world Alzheimer’s report 2016 estimates approximately 46.8 million people 
worldwide suffered from dementia in 2015 and this number will reach 131.5 million in 
2050 (Hebert et al., 2013). In principle, AD is an advanced stage of dementia, which 
gets progressively worse over time. AD accounts for around 50-70% of all dementia 
cases in the EU (reported by European commission on Health and Food Safety) 
(Europa.eu, 2017). Currently, there is no cure for AD but there is a worldwide attempt 
to find better ways to delay its onset, treat the disease and hamper it from developing 
(Yiannopoulou and Papageorgiou, 2013). 
 
One known major risk factor for AD is advanced age: the majority of people 
who are affected by Alzheimer’s are age 65 and older (Gleason, 2003; Qiu et al., 
2009). There is strong evidence that cardiovascular risk factors such as hypertension, 
stroke, high cholesterol, and diabetes are also associated with AD. In a minority of 
cases, there is a familiar background with mutations in disease-associated genes that 
can result in higher risk or earlier onset of the disease (Bruijn and Ikram, 2014). The 
origin of AD is not entirely known. Its pathophysiological process probably begins 
years, if not decades before the clinical diagnosis of dementia is made (Sperling et al., 
2014). This “preclinical” stage of AD might provide the chance for early diagnosis and 
therapeutic intervention (Fiandaca et al., 2014). The definite clinical onset of AD is 
difficult to conclude and once dementia is present, disease-modifying interventions 
may be no longer successful. Therefore, biomarkers are essential to anticipate the 
  2 
disease progression from preclinical AD phase to AD (Fiandaca et al., 2014; Sperling 
et al., 2011).  
 
 
1.2. Alzheimer’s disease pathology 
1.2.1. Clinical features 
People with AD start to forget and often show changes in their abilities and 
personality. Over time, short-term memory failure gradually turns into confusion about 
time and place that may turn to depression or even aggressive behavior in later stages. 
Currently, the AD diagnosis is based on the clinical history, neurological examination, 
and neuropsychological tests. Clinically, AD is characterized by gradual memory loss, 
progressive cognitive function, loss of language function, impaired executive 
functioning (difficulties with everyday decision making), problems with complex 
movement (apraxia), and personality changes. The first clinical diagnosis was 
established in 1984 and revised by the National Institute on Aging-Alzheimer’s 
Association (NIA-AA) workgroup in 2011 for a better understanding of the disease 
(Montine et al., 2012). There is no single test that confirms a person has Alzheimer’s 
or not. The diagnosis is made through a comprehensive evaluation that analyzes all 
possible causes of the observed dementia. AD generally starts as a condition referred 
to as mild cognitive impairment (MCI due to AD). Flicker et al. first used this term in 
1991; it refers to patients with mild cognitive dysfunction but has not yet affected daily 
life. MCI due to AD is often noted as a precursor or a transition stage between healthy 
cognitive aging and dementia. Research has demonstrated that persons with MCI due 
to AD have a higher chance of developing Alzheimer's disease in a few years in 
contrast to people with normal cognitive function (Flicker et al., 1991; Korolev, 2014). 
However, MCI does not always lead to AD. There are two types of MCI: amnestic and 
non-amnestic. A person with amnestic MCI (mainly affects the memory) has a higher 
risk of developing AD than non-amnestic MCI (affects thinking skills) (Petersen, 
Ronald C., 2009), who may suffer from AD from various other causes. 
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1.2.2. Neuropathological features 
The classic neuropathological hallmarks of AD are the presence of extracellular 
amyloid deposits, intracellular neurofibrillary tangles and early synapse loss (de Paula 
et al., 2009; Serrano-pozo et al., 2011). The gold standard for AD diagnosis is an 
autopsy-based (post mortem) pathology evaluation. Neuropathologically AD is 
characterized by the presence of extracellular deposition of amyloid beta (Aβ), 
intracellular accumulation of neurofibrillary tangles, synapse loss and 
neurodegeneration (Boyd-Kimball et al., 2005). Aβ is the main component of senile 
plaque deposits and tau is the component of neurofibrillary tangles (NFTs) (Heneka et 
al., 2010; Swomley et al., 2014). The National Institute on Aging/Reagan Institute of 
the Alzheimer Association (NIA-Reagan) Consensus published AD neuropathologic 
change in three parameters also known as “ABC score” (Hyman et al., 2012). 
Moreover, cognitive impairment in AD cases is strongly associated with synaptic 
dysfunction (Terry et al., 1991).  
 
“ABC score” (Aβ deposit score from Thal, NFT stage from Braak, Neuritic plaque score 
from CERAD): 
A. Aβ deposit score by Thal (Thal et al., 2002): 
A0: no amyloid deposit (Aβ) 
A1: phases 1 or 2 
A2: phase 3 
A3: phases 4 or 5 
B. NFT stage by Braak (Braak et al., 2011) 
B0: no neurofibrillary tangle (NFT) 
B1: stage I or II 
B2: stage III or IV 
B3: stage V or VI 
C. Neuritic plaque score by CERAD (Mirra et al., 1991) 
C0: no neuritic plaques 
C1: score sparse 
C2: score moderate 
C3: score frequent 
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Plaque deposits 
One of the main pathological lesions in AD patients is the senile or neuritic 
plaque. Senile plaques are abnormal extracellular accumulations of dystrophic 
neurites (abnormal neuronal processes) around a deposition of amyloid beta peptide 
in the gray matter of the brain (Baumann et al., 2017). Whereas diffuse deposit is not 
surrounded by dystrophic neuritis and has been called “preamyloid deposits” 
(Serrano-Pozo et al., 2011). In 1986, the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) generated a neuritic plaque scoring system for a 
standardized and validated measure of AD assessment, which was then used as a 
parameter in ABC score (Fillenbaum et al., 2008). This scoring ranks neuritic plaque 
density that histochemically identified in neocortex regions (Hyman et al., 2012).  
 
It was discovered in the mid-1980s that the deposits consist of Aβ aggregates 
(Laferla et al., 2007). The most common isoforms are Aβ40 and Aβ42 that are part of 
the Amyloid Precursor Protein (APP), generated by sequential cleavage of β- and γ-
secretases (Heneka et al., 2010;Serrano-Pozo et al., 2011).  Aβ is chemically “sticky”, 
which gradually forms into deposits that are hallmarks of Alzheimer’s. Aβ monomers 
can spontaneously assemble into soluble Aβ oligomers and insoluble fibrils. It has 
been widely reported that soluble oligomers are the most toxic form of Aβ to neurons  
(Heneka et al., 2015; Sakono and Zako, 2010; Sengupta et al., 2016). The human 
body has a break-down system to clear amyloid from the brain. However, the Aβ 
accumulation in AD cases is thought to be an imbalance in the production and 
clearance of this peptide causing the formation of amyloid deposits in specific brain 
regions (Kummer and Heneka, 2014).  
 
Braak and Braak in 1991 categorized gradual development of cortical amyloid 
deposits in three stages (Figure 1A) (Braak and Braak, 1991): 
Stage A: Low densities of amyloid deposits are found first in the isocortex 
(frontal, temporal, and occipital lobe). 
Stage B: Medium density of amyloid deposits in almost all of the isocortical 
association areas. 
Stage C: Essentially all isocortical areas (belt field and primary areas) show 
densely packed amyloid deposits. 
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Later in 2002, Thal et al. recommended the severity of Aβ deposits in 5 phases (Figure 
1B), which then used as Aβ deposit score on ABC scoring (Thal et al., 2002). The 
main analysis of Thal’s phase model is that in the brain, Aβ spreads systematically 
(Hyman et al., 2012).  
Phase 1:  Aβ deposits start to develop in the neocortex. 
Phase 2:   Continued to the allocortical regions. 
Phase 3: Spread to diencephalon, basal forebrain and striatum. 
Phase 4: Then midbrain and medulla oblongata. 
Phase 5: Finally, into the pons and the cerebellum. 
 
 
Figure 1. The pathological evolution of amyloid deposits in AD. (A) The severity of Aβ 
deposits adapted from Braak and Braak (Braak and Braak, 1991). Amyloid deposits 
spread through the brain as the disease progresses. Aβ deposits develop first in one 
  6 
or more sites in the frontal, temporal, and occipital lobe (Stage A). They are observed 
later in almost all of the isocortical association areas. (Stage B). In severe cases of 
AD, Aβ deposits are found densely packed in all isocortical areas (Stage C). (B) The 
anatomical distribution of Aβ taken from Thal et al (Thal et al., 2002). Thal’s first phase 
shows Aβ deposits only in the neocortex (green). The second phase is defined by 
additional spreading in allocortical brain regions (red). Phase 3 shows Aβ deposits in 
the striatum and the interbrain. Several nuclei in the brainstem become affected in 
phase 4, and phase 5 is described by the presence of Aβ deposits in the cerebellum 
and other brain areas.  
 
 
Neurofibrillary Tangles 
Another common primary marker of AD is neurofibrillary tangle. NFTs are 
characterized by intra-neuronal aggregates of insoluble hyperphosphorylated 
microtubule associated protein tau, which become extra-neuronal after tangle-bearing 
neurons die (Braak and Braak, 1991; Serrano-pozo et al., 2011). Tau proteins are 
proteins that function as microtubules stabilisators and a cellular transport system. 
The loss of normal tau function, combined with a toxic gain of function (the 
aggregation) could compromise transport along the long nerve cell projections, the 
axons, and contribute to degeneration beginning with the important signaling 
synapses at the end of the axon. Furthermore, formation of large NFTs inside the cell 
can result in cell death and the number of neurofibrillary tangles is linked with the 
severity of AD. There is speculation that the formation of NFTs and amyloid 
aggregation are interlinked for example by toxic amyloid oligomers. The exact 
mechanism however is not finally resolved (Castellani et al., 2010; Gendron and 
Petrucelli, 2009). 
 
Figure 2 shows Braak stages of NFTs (on ABC score). The locus coeruleus is 
one of the earliest places to develop NFTs, which may act as a seed for spreading of 
the pathology throughout the brain before Aβ accumulation (Braak and Del Tredici, 
2011; Braak et al., 2011; Satoh and Lijima, 2017). Locus coeruleus is a nucleus in the 
brainstem, which has roles in attention, emotion, memory and cognition (Sara, 2009; 
Satoh and Lijima, 2017). 
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a) Early stage: NFTs first appear in the transentorhinal region (stage I), 
followed by the entorhinal region and hippocampus (stage 
II). 
b) Middle stage: NFTs accumulate in the basal neocortical areas of the 
temporal lobe (stage III) then insular and basal frontal areas 
(stage IV). 
c) Late stage: NFTs spread to all prefrontal cortex and neocortical areas 
(stage V) than the primary sensory, motor, and visual areas 
(stage VI).  
 
 
Figure 2. The pathological evolution of neurofibrillary tangle in AD, adapted from Braak 
and Braak (Braak et al., 2011). NFTs first develop in the locus coeruleus, as well as 
in the transentorhinal and entorhinal regions (stages I and II). Then spread through 
the neocortex (stages III and IV), followed by large parts of the neocortex (stages V 
and VI). 
 
 
Synaptic loss and neurodegeneration 
The loss of synapses is also considered a hallmark of AD. Whittaker’s group 
first mentioned the concept of “Synaptosome” in their article in 1964, which considered 
as isolated nerve terminals (Whittaker et al., 1964). The synapses consist of three 
major components: the presynaptic membrane (also known as axon terminal), a 
synaptic cleft, and a postsynaptic membrane (also known as dendritic spine) 
(Whittaker et al., 1964). The pre- and the postsynaptic membranes are exclusively 
noticeable by visible densities along their plasma membranes. Their function is for 
neurons communication (electrical or chemical). The synaptic proteins interaction 
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controls functions of learning and memory (Bai and Witzmann, 2007; Swomley et al., 
2014).  
 
Diverse studies have shown the connection between cognitive impairment and 
synaptic dysfunction as a start of AD pathogenesis. Synapses dysfunction is 
considered to take place before the neuronal degeneration and death, which make the 
synapses as an essential therapeutic target (Boyd-Kimball et al., 2005; Chang et al., 
2013). Prior studies have demonstrated significant decreases in synaptic density, 
which are area-specific in AD brain (Terry et al., 1991). Davies et al. showed 14% to 
38% lesser number of synapses per surviving neuron in the frontal and temporal cortex 
and around 25% to 36% deficit in synaptic density (Davies et al., 1987). In AD patients, 
the remaining synapses are impaired functionally. Though they appear to be intact 
structurally, they may be dysfunctional (Yao et al., 2003). 
 
 
1.3. Generation of amyloid beta 
The Aβ is derived from proteolysis of APP, which encode gene is located on 
chromosome 21 in humans (Goate et al., 1991). APP is a transmembrane glycoprotein 
that is expressed by neurons, astrocytes and microglia. APP can be processed by one 
of two pathways (Figure 3). Around 90% is processed through the non-amyloidogenic 
pathway, and 10% the amyloidogenic pathway, however these ratios can change as 
a result of environmental factors, mutations and the age of the individual. The cleavage 
products from both pathways may have crucial roles in neural function and 
development (Plácido et al., 2014). 
 
In non-amyloidogenic pathway, APP is first enzymatically cleaved by α-
secretase, of which three enzymes have been identified, belonging to the ADAM 
family: ADAM9, ADAM10 and ADAM17 (a disintegrin and metalloprotease family 
enzyme). The two yield fragments are the soluble secreted amyloid precursor protein-
α or N-terminal fragment (sAPPα) and carboxy-terminal fragment (CTFα). This 
cleavage by α-secretase occurs within the Aβ domain, hence preventing the 
generation of the Aβ peptide. While Aβ is neurotoxic, studies suggest that sAPPα may 
be involved in neuronal survival and has a neuroprotective role. Furthermore, CTFα 
undergoes an additional cleavage by γ-secretase to generate a soluble N-terminal 
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fragment (P3) and a membrane-bound C-terminal fragment or amyloid precursor 
protein intracellular domain (AICD or APP intracellular domain) (Furukawa et al., 1996; 
Laferla et al., 2007; Mattson, 1997).  
 
In the amyloidogenic pathway, APP is initially cleaved by β-secretase (BACE; 
β-site APPcleaving enzyme), generating a soluble N-terminal fragment (sAPPβ), and 
C-terminal fragment (CTFβ) within the membrane. CTFβ is then cleaved by the γ-
secretase, yielding AICD (the same as non-amyloidogenic pathway) and soluble Aβ 
(Furukawa et al., 1996; Laferla et al., 2007; Mattson, 1997). This cleavage generates 
two mainly toxic species, Aβ1–40, and Aβ1–42 (more amyloidogenic) at a ratio of 10:1. 
Aβs rapidly aggregate to form oligomers and the insoluble amyloid fibrils, which disrupt 
neuronal function (Chow et al., 2011; Qu et al., 2016).  
 
 
 
Figure 3. The processing of amyloid precursor protein (APP). APP can be cleaved by 
α-, β-, and γ-secretases, which undergo non-amyloidogenic (left) or amyloidogenic 
(right) processing. The non-amyloidogenic pathway, cleaved by α-secretase yields in 
fragments of the soluble secreted amyloid precursor protein-α (sAPPα) and carboxy-
terminal fragment α (CTFα). Furthermore, CTFα undergoes an additional cleavage by 
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γ-secretase resulting P3 and amyloid precursor protein intracellular domain (AICD). In 
the amyloidogenic pathway, APP is first cleaved by β-secretase generating a soluble 
secreted amyloid precursor protein-β (sAPPβ), and carboxy-terminal fragment β 
(CTFβ). CTFβ is then cleaved by the γ-secretase, yielding AICD and Aβ. 
 
 
1.4. Genetics of Alzheimer’s disease 
Ageing is the most influential known risk factor of AD. Family history is the 
second greatest risk factor for the development of AD. Based on the age of onset, AD 
is divided into 2 types: early-onset AD (EOAD) and late-onset AD (LOAD). EOAD or 
also called Familial Alzheimer’s Disease (FAD) represents the minority of all AD cases 
and affects people before the age of 65. Three genes are considered as the main risk 
factors of EOAD:  amyloid precursor protein (APP) on chromosome 21, presenilin 
1 (PSEN1) on chromosome 14, and presenilin 2 (PSEN2) on chromosome 1. Each of 
these mutations plays a role in APP breakdown and can form abnormal proteins. This 
breakdown generates harmful forms of amyloid deposit in the brain (Bertram and 
Tanzi, 2005; Goate et al., 1991; Tanzi and Bertram, 2005).  
 
The majority of people with AD have LOAD or Sporadic Alzheimer’s Disease 
(SAD), which symptoms become visible at the age of 65 and over. The causes of 
LOAD are not fully understood though it is predicted as a combination of factors of 
genetic, lifestyle and environmental, which may affect a person’s risk to develop the 
disease. The important genetic risk factor for LOAD is APOE gene, located on 
chromosome 19. APOE comes in different forms: APOE ε2, APOE ε3, and APOE ε4. 
Both EOAD and LOAD can happen in people with a positive family history of AD 
(Bertram and Tanzi, 2005; Goate et al., 1991; Tanzi and Bertram, 2005).  
 
 
1.5. Inflammatory process 
Another important sign of AD is neuroinflammation; it is a complex process that 
has both beneficial aspects in maintenance of brain homeostasis and facilitates injury 
resolution (degenerative, infection and tissue damage); but also can be detrimental if 
sustained chronically, over years and decades (Schwartz et al., 2013; Sochocka et al., 
2017). Increasing proof proposes neuroinflammation as an essential contributor in AD 
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pathogenesis (Heneka et al., 2010, 2015). Though the exact disease stage at which 
neuroinflammation begins in AD is unknown, it may be one of the earliest events 
associated with the disease process (Qu et al., 2014a; Wyss-coray and Rogers, 2012). 
The term “neuroinflammation” describes the inflammatory response in the central 
nervous system (CNS) triggered by autoimmunity, infection, or toxins that causes glial 
cells to accumulate (Glass et al., 2010).  
 
Under pathological conditions such as inflammation, altered neuronal function, 
infection, injury and ischemia, microglia are activated (physiologically in inactive state), 
which change the morphology of microglia, from ramified (resting) to ameboid (active) 
(Wang et al., 2015). Microglia detects pathogens via pattern recognition receptors 
(PRRs) that include specific toll-like receptors (TLRs), nucleotide-oligomerization 
binding, C-type lectin receptors and domain (NOD) proteins (Sterka and Marriott, 
2006). These receptors recognize pathogen-associated molecular patterns (PAMPs) 
or damage-associated molecular patterns (DAMPs) and initiate the cellular defense 
mechanisms (Heneka et al., 2015). Astrogliosis, which demonstrated by an increase 
in the size, number and motility of astrocytes is also seen in AD. Once activated, 
microglia and astrocytes produce several proinflammatory signal molecules, including 
cytokines, chemokines, complement molecules, growth factors and cell adhesion 
molecules (Bai and Witzmann, 2007; Heneka et al., 2015).  
 
Microglia activation also contributes to the release of reactive oxygen species 
(ROS) and nitric oxide (NO) through the activation of myeloperoxidase, NADPH 
oxidise and inducible NO synthase (iNOS or NOS2) (Heneka et al., 2014). Previous 
studies reported increased levels of nitrosylated proteins in AD brain and cerebral 
spinal fluid (CSF). The increase of oxidative stress modification indicates inflammation 
as an important source in the pathogenesis of neurodegenerative disease (Galasko 
and Montine, 2010; Zahid et al., 2014). Activated microglia and astrocytes are 
characteristically found surrounding and engulfing the A senile deposits (Glass et al., 
2010).  
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1.5.1. Mechanisms of nitric oxide synthesis 
Reactive oxygen/nitrogen species (ROS/RNS) are commonly produced at 
relatively low concentrations by all cell types (such as macrophages, monocytes) and 
have a role as physiological messengers of intracellular signaling pathway required 
for immune response and cell growth (Finkel, 2011; Nakamura et al., 2012). 
Nonetheless, exposure to environmental toxins, neuroinflammatory stimuli 
(pathogens, irritants or damaged cells), Aβ oligomers and also the normal process of 
aging can provoke redox imbalance, leading to nitrosative/oxidative stress (Nakamura 
et al., 2012). An imbalance of this system by increased oxidant production and 
reduction of antioxidants contributes to neuronal cell damage and results in 
neurodegeneration (Martínez-Ruiz et al., 2011). Additionally, peripheral inflammation 
also contributes to neuroinflammation by increasing the blood brain-barrier (BBB) 
permeability and brain inflammatory responses such as glial cells activation, which 
release ROS, chemokines and pro-inflammatory cytokines (Takeda et al., 2013). 
 
 RNS are derived mainly from O2- and nitric oxide (NO), a small, diffusible 
messenger (Mangialasche et al., 2009). NO is a free radical that is synthesized 
through the conversion of L-arginine to L-citrulline and NO via nitric oxide synthase 
(NOS) enzymes (Chung, 2007; Habib and Ali, 2011). NO contributes to numerous 
physiologic responses such as neurogenesis, vasculature vasodilation, synaptic 
neurotransmission, inflammation, and apoptosis (Forstermann et al., 1994; Mannick 
and Schonhoff, 2002). NO is a signaling molecule or intracellular messenger that 
coordinates the communication between endothelial cells and immune cells. It is 
involved in both central and peripheral nervous system as a host protection from 
infectious organisms (bacteria, viruses and other microorganisms), which can induce 
the death of host immune cells (Bogdan et al., 2000).  
 
There are three isoforms of the NOS enzyme: neuronal (also known as nNOS 
or NOS1), inducible (also known as iNOS or NOS2), and endothelial (also known as 
eNOS or NOS3). nNOS and eNOS are expressed constitutively and Ca2+ dependent, 
while iNOS is inactive under non-pathological conditions and is Ca2+ independent. 
Each isoform has specific functions (Förstermann and Sessa, 2012): The human 
nNOS gene is located in chromosome 12 and expresses NO mainly in neurons 
(Knowles and Moncada, 1994; Viaro et al., 2000). Its functions are synaptic plasticity, 
  13 
cell communication, relaxation of smooth muscle and blood pressure regulation (Viaro 
et al., 2000). eNOS produces NO in endothelial, blood vessels and is involved in 
vascular tone regulation (vasodilatation) and platelet function (adhesion and 
aggregation) (Knowles and Moncada, 1994; Viaro et al., 2000). The expression of the 
inducible nitric oxide synthase (also known as inflammatory NOS) has been defined 
as a result of the inflammatory processes, which come with tissue damage, infection, 
or disease (Colton et al., 2008; Heneka and Feinstein, 2001). In the brain, iNOS is 
produced in microglia cells, astrocytes and in lesser amount in endothelial cells 
(Heneka and Feinstein, 2001). The iNOS gene coding is located in chromosome 17 
(Knowles and Moncada, 1994). iNOS is not usually expressed in cells and it is induced 
upon stimulation by proinflammatory cytokines (such as tumor necrosis factor 
alpha/TNF-α, interleukin-1/IL-1 and interferon gamma/IFN-g) and lipopolysaccharide 
(LPS) (Green et al., 1994). 
 
 
1.5.2. Protein S-Nitrosylation and denitrosylation 
S-nitrosylation of cysteine (SNO) is one of the most important post-translational 
modifications (PTM) induced by NO (Nakamura et al., 2013). SNO is a reversible PTM 
with covalent addition of a nitrosyl group (NO) to the cysteine (Cys) thiol group (Anand 
and Stamler, 2012). It is observed as an essential redox signaling mechanism in the 
regulation of many cellular and physiological functions. In normal physiological 
conditions, SNO can influence protein-protein interaction, regulate (by activation or 
inhibition) protein activity, affect protein localization, alter protein aggregation, promote 
conformational changes and regulate cell signal transduction pathways (Choi et al., 
2000; Qu et al., 2011; Uehara et al., 2006). In contrast, under pathological conditions, 
excess SNO can trigger protein misfolding, mitochondrial dysfunction, and ER stress, 
which leads to synaptic degeneration and cell death (Nakamura and Lipton, 2007).  
 
Due to an increasing number of PTM protein identifications, a central database 
(dbSNO 2.0) is made to collect all datasets for S-nitrosylated proteins from different 
sources, which is available at http://dbSNO.mbc.nctu.edu.tw (Lee et al., 2012b). The 
scope of SNO proteins depends on the level of both nitrosylation and denitrosylation 
(Benhar et al., 2009). S-nitrosylated protein formation could be counterbalanced by 
denitrosylation, which is involved in the NO removal from S-nitrosylated cysteine, 
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through non-enzymatic and enzymatic mechanism (Zhao et al., 2015). Non-enzymatic 
mechanism is mediated by free metal ions of iron or copper. Enzymatic mechanism is 
mediated by enzymes such as S-nitrosoglutathione reductase (GSNOR), protein 
disulfide isomerase (PDI) and thioredoxin reductase (TrxR) (Benhar et al., 2009; 
Nakamura et al., 2012). 
 
 
1.5.3. S-nitrosylation (SNO) in neurodegenerative disorder 
During aging, there is an increase of free radical and a decrease of antioxidant, 
which may contribute to the neurodegenerative development such as AD (Sayre et al., 
2008). It has been shown in previous publications that nitric oxide (NO) has an 
important part in neurodegeneration process (Nakamura and Lipton, 2016; Reczek et 
al., 2006). In neurodegenerative disorders, aberrant SNO can propagate synaptic 
injury, mitochondrial dysfunction, protein misfolding, and neuronal death (Nakamura 
et al., 2013). In AD, studies have shown that neuroinflammatory stimuli such as Aβ 
oligomers can stimulate microglia cells. Once activated, microglia cells recruit 
astrocytes, which boost the inflammatory response on the extracellular Aβ deposits 
(Zhao et al., 2015). This AD neuroinflammatory component is then characterized by 
acute-phase response of cytokine, complement cascade activation and induction of 
iNOS (Heneka et al., 2010; Wallace et al., 1997).   
 
 
1.5.4. Detection and analysis of SNO-proteins 
The detection and quantification of S-nitrosylation has been a difficult task due 
to the low abundant and labile nature of the modification (sulfur-nitrogen bond in S-
nitrosothiol) (Qu et al., 2014a). Nitrosothiols can be detected using several ways such 
as chemiluminescence, colorimetric, fluorometric, S-nitrosylated cysteine antibody, 
and mass spectrometry (MS) analysis (Chen et al., 2013; Ju et al., 2015).  
 
The first and frequently used method for SNO detection is the biotin switch 
technique (BST) developed by Jaffrey and Snyder in 2001. This method utilizes a 
replacement strategy by adding a stable biotin-label on the SNO modification, allowing 
their detection and identification by anti-biotin antibodies or mass spectrometry 
(Jaffrey and Snyder, 2001). General approaches for quantitative SNO proteomics are 
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two-dimensional difference gel electrophoresis (2D-DIGE) or liquid chromatography 
(LC) followed by mass spectrometry. To achieve an optimal result, a combination of 
protein enrichment and/or fractionation (one- or 2D-DIGE, liquid chromatography) and 
identification technique (Western blotting, tandem mass spectrometry) is needed (Bai 
and Witzmann, 2007). One of the recent SNO detection is NitroDIGE, which combined 
2D-DIGE with modified BST using fluorescence dye CyDyeTM (Qu et al., 2014b). 
 
One of the fractionation procedures is HPLC (high performance liquid 
chromatography) (Issaq et al., 2002).  It depends on their pumps to undergo a 
liquid solvent containing the sample mixture via a column loaded with a 
solid adsorbent material (Issaq et al., 2002). Each sample component reacts slightly 
different with the adsorbent material, generating different flow rates for the each 
component and causing the segregation of the components when they flow out of the 
column (Issaq et al., 2002; Mitulovic and Mechtler, 2006). 
 
Most of the methods address high amounts of starting materials that range 
around 100 to 500 μg of protein lysate (Wojdyla and Rogowska-Wrzesinska, 2015). 
Moreover, it is a common procedure to use NO-donors as an induction to analyze 
SNO modification sites. Making it difficult for results comparison of studies using NO 
donors with the in vivo situation, where cysteine S-nitrosylation depends on the 
unknown concentrations of nitrosylating compounds (Zareba-Koziol et al., 2014). 
Therefore, endogenous SNO level identification that is produced from sub-fractionated 
compartments such as synaptosomes need high sensitivity and specificity of the 
detection (Wijasa et al., 2017).  
 
In the current approach, an MS-based, isobaric tag labeling strategy was 
proposed, where peptides are linked with various tags with the same mass and 
fragmented to generate reporter ions of different mass (Dayon and Sanchez, 2012). 
In a classic bottom-up proteomics workflow, proteins are enzymatically digested by 
proteolytic digestion to generate peptides, which are then labeled with various isobaric 
tags (Zhang et al., 2013). Analogous with BST, the iodoTMTTM 126-131 labeling 
reagents are used as a substitute chemistry of SNO modifications (Qu et al., 2014a). 
This approach has been rarely described with low amounts of starting material and 
under basal condition (with NO donor treatment) (Wijasa et al., 2017). Despite 
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introduced in 2012, this approach has been barely described in the literature utilizing 
endogenous condition samples (without NO donor treatment) and low amounts of 
starting material. 
 
 
1.6. Synaptosomes preparations for proteomic analysis 
Various techniques have been established for synaptosome isolation using 
different centrifugation and buffer reagents, such as sucrose, Ficoll/sucrose or Percoll 
density gradient centrifugation, all of which result in purifying a crude synaptosome 
fraction from the contamination (Jaffrey and Snyder, 2001; Scheff et al., 2014). Density 
gradient centrifugation is a common procedure used for subcellular fractionation such 
as synaptosome for further analysis (Kiss et al., 2016). Sucrose solution is the most 
common used solution for density manipulation (Clayton and Shadel, 2014). In the 
process, the sample is first lysed to break the cell membrane then layered on a 
discontinuous sucrose density gradient (Wijasa et al., 2017). After repeated 
centrifugations using swinging bucket rotors, the density separation generates 
sediment called pellet (the full protocol is described on the material and methods 
section).  
 
The purity of synaptosome isolation can be confirmed by western blotting 
analysis or examined under an electron microscope (EM) (Bai and Witzmann, 2007). 
Western blotting is a widely used analytical technique to detect specific proteins in a 
sample using certain markers (Jensen, 2012). In a western blot, gel electrophoresis is 
used for separation of the native proteins and their fragments based on their size and 
charge. Polyacrylamide gel is usually utilized for the electrophoretic separation of 
proteins, and SDS is mainly used as a buffer (also in the gel) thus all proteins will be 
in a uniform negative charge (proteins can be charged positively, negatively, or 
neutrally) (Towbin et al., 1979). This is known as SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). After the electrophoretic separation, the proteins are 
transferred to a membrane (nitrocellulose or PVDF), which are then blocked with 
Bovine Serum Albumin (BSA) or milk to prevent non-specific binding of the antibody. 
The membrane then stained with antibodies specific to the target protein (first 
antibody) and a secondary antibody that recognizes the first antibody staining for the 
detection (Towbin et al., 1979). There are many technical approaches used for 
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synaptosomal proteome analysis; each has its own advantages and disadvantages 
(Nesvizhskii, 2007). Consequently, the chosen approach can affect the study outcome 
and therefore has to be done carefully (Bai and Witzmann, 2007).  
 
 
1.7. Quantitative proteomic 
Mass spectrometry-based proteomics facilitates large-scale analysis of 
biological systems, as it allows sensitive and unbiased detection of proteins/peptides 
and PTM such as s-nitrosylation (Ong, 2010). Proteomic studies can be performed 
using various biological samples such as whole tissue samples, isolated cells and 
body fluids. Quantitative proteomics comprises analytical techniques to determine not 
only the identity but also relative or absolute concentrations of protein components in 
a sample. For mass spectrometry, proteins are typically digested with specific 
proteases, for example trypsin, which generates specific sets of peptides, following 
ionization and analysis by MS instruments (Kito and Ito, 2008).  
 
Tandem mass spectrometry (MS/MS) has been broadly used in proteome 
analysis, where an ion peptide is then selectively isolated and fragmented to generate 
an MS/MS spectrum. The pattern of these fragment ions is comparable with theoretical 
ones calculated from protein sequences in databases. If the MS/MS spectrum 
calculated for a peptide shows a reliable match with one of the theoretical spectra, the 
peptide is then selected for the theoretical spectrum calculation (Kito and Ito, 2008; 
Tuli and Ressom, 2009). MS-based proteomics enables quantitative analysis of post-
translational modifications and protein abundance in cell, tissue and whole organism 
(Ren et al., 2014). 
 
In order to generate reliable and consistent data sets, an extensive internal 
quality control of the procedure is required. The use of an internal standard can aid to 
control the variability in a quantitative analysis. It should be added in the analytical 
procedure as early as possible and treated equally to other samples (Ong, 2010). 
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1.8. Data analysis and protein identification 
One of the ways to visualize the significant differential abundance (between two 
conditions or more) from proteomic data is by significant fold change assessed by 
statistical analysis such as Limma, RankProduct (RP) and bootstrap analysis 
(Mukherjee et al., 2003a; Pursiheimo et al., 2015). Limma, RankProduct and bootstrap 
analysis were first developed for microarray data which also work well for proteomics 
data (Breitling et al., 2004; Schwammle et al., 2013). One of the well-known problems 
of proteomics data analysis is missing values. This problem became worse when the 
detection of significant changes on the peptide level is wanted (Schwammle et al., 
2013; Webb-Robertson et al., 2015). In order to solve this problem, Schwammle et al 
in 2013 investigated and optimized the performance of three statistical approaches 
(standard t-test, Limma and RankPrduct) using experimental data sets with varying 
missing values (Schwammle et al., 2013).  
 
 Schwammle et al. recommended the combined use of Limma and RankProduct 
as a new and excellent way to detect significant changes in large quantitative data 
sets from mass spectrometry experiments (Schwammle et al., 2013). Limma or short 
for “linear models for microarray data” is a modified version of standard t-test, which 
fit the statistic model of linear model (Pursiheimo et al., 2015). While RP is based on 
the statistic model of rank statistic (ranks of fold changes) for the analysis (Breitling et 
al., 2004). Limma and RankProduct are well-established methods for statistical 
analysis of large data sets with missing values. The tests provide more sensitive and 
reliable results than standard t-test (Schwammle et al., 2013). Nonetheless, both tests 
perform optimally on different types of data sets. In general, LM performs better for 
high variation samples with low amounts of missing values. While RP is a more 
suitable test for data sets with more missing values and low variation of regulated 
values. The requirement to achieve high-confident results using this combination is a 
large data set (more than 1000 features) (Schwammle et al., 2013).  
 
Another statistical analysis for handling the proteomics data is the bootstrap 
method/bootstraping (Mukherjee et al., 2003a). This method was first introduced in 
1979 by Bradley Efron (Efron and Tibshirani, 1993). Bootstrapping is a random 
resampling method with replacement from the sample data (from a population) to 
calculate confidence intervals on interest parameters (Mukherjee et al., 2003a). 
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Bootstrapping can be used for insufficient/small samples of the same size which then 
repeatedly drawn in a large number of times. So the same replicate can occur more 
than once in the data table with the same or different condition (Efron and Tibshirani, 
1993; Mukherjee et al., 2003a).  
 
 
1.9. Aim of the thesis 
Aim of this study was to characterize NOS2-dependent S-nitrosylation on 
synaptic proteins to discover new potential biomarker candidates of 
neuroinflammation in early AD stages. In order to achieve that, synaptosomes were 
isolated from transgenic mice and human post mortem brain tissues.  
 
A biomarker refers to a material used as a measurable indicator of some 
biological state (normal and pathogenic biological process) (Liu et al., 2014). Changes 
in the brain begin years prior to clinical onset and diagnosis of AD. Until now, 
diagnosing AD in early stage can be difficult and challenging (Fiandaca et al., 2014). 
Thus the biomarker development for AD is important to enhance early diagnosis and 
stimulate the development of new therapies (Chintamaneni and Bhaskar, 2012). It has 
been known for some years that synapses are the important target because synapse 
degeneration occurs early during AD pathogenesis. To identify potential candidate 
biomarkers in synaptic proteins and determine the effect of inflammation on AD 
pathogenesis, mass spectrometry (MS)-based proteomic was used on AD 
synaptosomal samples from mouse and human groups.  
 
To analyze the mouse data thoroughly, the age effect of each genotype 
(comparing 12-month to 3-month-old mice) and the genotype effect on old mice 
(APP/PS1 and NOS2 knockout effect) were analyzed. The age effect on WT mice was 
used as a control, which shows the differentially regulated proteins during healthy 
aging. While the age effect on APP/P1 mice was used as a pathological aging. AD 
progression was analyzed in human samples by comparing the disease stages (MCI-
Control, AD-MCI, and AD-Control) (Figure 4).  
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Figure 4. Overview of the experimental groups used in murine and human samples.  
A) SNO-proteins/peptides from murine synaptosomes were examined using a chain 
of comparisons to identify the age-dependent, APP/PS1-dependent and NOS2-
dependent effects. The experimental groups (n = 12 mice/group) were 3-month and 
12-month-old wild type (WT), NOS2ko (NOS2 knockout mice or NOS2 -/-), APP/PS1 
(transgenic mice carrying the human amyloid precursor protein and presenilin1 gene) 
and APP/PS1/NOS2-/- (transgenic mice carrying the human amyloid 
precursor protein, presenilin1 gene crossed with NOS2ko). B) SNO-proteomes from 
human synaptosomes (n = 20 human samples/group) were examined using the 
comparison of disease stage. 
 
This thesis provides information about: 
• Method optimization of quantitative proteomics on synaptosomal samples 
• The efficiency of the iodoTMTTM protocol when applied to the analysis of 
synaptosomal samples 
• Technical variances of the method as well as the comparability of findings with 
previous published results in the field. 
• Characterization of NOS2-dependent S-nitrosylation on synaptic proteins  
• New potential biomarker candidates of neuroinflammation in early AD stage
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APP/PS1/NOS2ko 12mAPP/PS1 12mWT 12m
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2. Material and methods 
2.1. Materials 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit anti-glutamate receptor 1 
(GluR1) 
Merck KGaA, Darmstadt, 
Germany 
Cat# ab1504, 
RRID: 
AB_2113602 
Mouse anti-lamin B1 
Proteintech Group Inc., Chicago, 
USA 
Cat# 66095-1-Ig, 
RRID: 
AB_11232208 
Rabbit anti-NMDA receptor 2B 
(NMDAR2B) 
Merck KGaA, Darmstadt, 
Germany 
Cat# ab1557p, 
RRID: 
AB_11214394 
Mouse anti post-synaptic 
density (PSD95) 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# MA1-046, 
RRID: 
AB_2092361 
Rabbit anti-synaptophysin Abcam Inc., Cambridge, UK 
Cat# ab52636, 
RRID: AB_882786 
Mouse anti-tubulin 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 62204, 
RRID: 
AB_1965960 
Chemicals 
4-(2-
Aminoethyl)benzenesulfonyl 
fluoride hydrochloride (AEBSF) 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# A8456 
1.4-Dithiothreit (DTT) 
Carl Roth GmbH &Co. KG, 
Karlsruhe, Germany 
Cat# 6908 
4X Protein Sample Loading 
Buffer 
LI-COR Inc., Lincoln, Nebraska, 
USA 
Cat# P/N 928-
40004 
Aceton 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# 650501-1L-M 
C18 Spin Columns 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 89870 
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Dimethylformide (DMF) 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# TS-20673 
Dimethyl sulfoxide (DMSO) 
Applichem GmbH, Darmstadt, 
Germany 
Cat# A1584 
Ethylene diamine tetraacetic 
acid (EDTA) 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 15575020 
Ethylene glycol tetraacetic acid 
(EGTA) 
Carl Roth GmbH &Co. KG, 
Karlsruhe, Germany 
Cat# 3054 
Formic Acid (FA) 
Sigma-Aldrich Chemie, Munich, 
Germany 
Cat# 06473-100ML 
HENS buffer 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 90106 
Hydroxylamine 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 90115 
Immobil ized Anti -TMTTM 
Resin  
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 90076 
Iodoacetamide (IAM) 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# A3221-10VL 
LC/MS grade acetonitrile (ACN) 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 51101 
LC/MS grade methanol 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# A456-4 
Methyl methanethiosulfonate 
(MMTS) 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 23011 
Nitrocellulose Membranes 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 88013 
Nonidet (NP-40) 
United State Biological Inc., 
Salem, Massachusetts, USA 
Cat# N3500 
NuPAGE™ 4-12% Bis-Tris 
Protein Gels 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# NP0321BOX 
NuPAGE MES SDS Running 
Buffer (20X) 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# NP0002 
NuPAGE™ Transfer Buffer 
(20X) 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# NP0006 
PageRulerTM Prestained 
Protein Ladder (10 to 180 kDa) 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 26616 
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PBS powder without Ca2+, Mg2+ 
Biochrome Gmbh, Berlin, 
Germany 
Cat# L 182-01 
cOmplete protease inhibitor 
cocktail 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# 04693116001 
Sodium ascorbate 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 
AC352681000 
Sodium chloride (NaCl) 
Applichem GmbH, Darmstadt, 
Germany 
Cat# 131659.1214 
Sodium deoxycholate (NaDOC) 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# D6750 
Sodium Dodecyl Sulfate (SDS) MP Biomedicals  Cat# 04811030 
Sodium fluoride (NaF) 
Carl Roth GmbH &Co. KG, 
Karlsruhe, Germany 
Cat# P756 
Sodium orthovanadate (Na3VO4) 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# S6508 
Sodium pyrophosphate dibasic 
(Na2H2P2O7) 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# P8135 
Sucrose 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# S9378 
Tandem mass tag (TMT) 
Elut ion Buffer  
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 90104 
trifluoroacetic acid (TFA)  
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# 302031 
Tris-Acetat 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# T8280 
Tris (hydroxymethyl) 
aminomethane 
Carl Roth GmbH &Co. KG, 
Karlsruhe, Germany 
Cat# 9090 
Trypsin 
Serva Electrophoresis GmbH, 
Heidelberg, Germany 
Cat# 37294 
Tween-20 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# P9416 
Water for HPLC 
Sigma Aldrich Co. LLC., Munich, 
Germany 
Cat# 34877 
Critical Commercial Assays 
IodoTMTTM sixplex Label Thermo Fisher, Scientific, Cat# 90102 
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Reagent Set Waltham, USA 
Pierce BCA Protein Assay Kit 
Thermo Fisher, Scientific, 
Waltham, USA 
Cat# 23225 
Experimental Models: Organisms Strains 
Mouse: BC57/Bl6 
The Jackson Laboratory, Bar 
Harbor, Maine, USA 
RRID:IMSR_JAX:0
00664 
 
Mouse: APP/PS1 
The Jackson Laboratory, Bar 
Harbor, Maine, USA 
https://www.jax.org
/strain/005864 
Mouse: NOS2-/- 
The Jackson Laboratory, Bar 
Harbor, Maine, USA 
http://jaxmice.jax.or
g/strain/002609.ht
ml 
Mouse: APP/PS1/NOS2-/- UKB Bonn animal facility (HET3) N/A 
 
 
2.2. Brain samples 
2.2.1. Mice 
 Two age groups were chosen to reflect the age effect on AD progression, 3-
month and 12-month-old mice. To analyze the genotype effect in aged mice, four age-
matched male transgenic animal groups (APP/PS1, NOS2-/-, APP/PS1/NOS2-/- and 
wild type) were used in this study that all shared the BC57/Bl6 genetic background. 
As AD models, hemizygous double transgenic mice APP/PS1 expressing a chimeric 
mouse/human amyloid precursor protein (Swedish mutation) and a human PS1 Δexon 
9 mutation (Jankowsky et al., 2001) were studied, using wild type (WT) as controls. 
NOS2 knockout or NOS2-/- (additional information can be found at 
http://jaxmice.jax.org/strain/002609.html) and APP/PS1/NOS2-/- mice were used to 
see the effect of iNOS-derived nitric oxide (inflammation) in wild type control and 
APP/PS1 background respectively. APP/PS1 +/- and NOS2-/- mice were bred to 
generate the litters on one of the group (APP/PS1/NOS2-/-) that used in this study. 
The deletion of inducible nitric oxide synthase in an APP/PS1 background was used 
as a way to understand better the role of NO (iNOS-derived NO) in altering chronic 
neurological disease. Mice were maintained under standard conditions at temperature 
of 22°C and a 12 h/12 h light/dark cycle, housed in groups and given free access to 
food and water. Mice were anesthetized and transcardially perfused with ice-cold 
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normal saline shortly prior to synaptosome isolation. The mice numbers were n = 20 
per experimental group. Whole brain hemispheres without cerebellum and brainstem 
were used for protein extraction.  
 
 
2.2.2. Human samples 
Ninety frozen post mortem human brain tissues from the cortical area (n = 30 
healthy control, n = 30 mild cognitive impairment/MCI and n = 30 Alzheimer’s 
disease/AD) were obtained from Banner Sun Health Research Institute (BSHRI) Brain 
and Body Donation Program in Sun City, Arizona (Beach et al., 2015). These three 
human groups were matched with consideration of age (above 65), sex, post mortem 
interval / PMI (less than 4 hours), MMSE, Braak stage, and ApoE (Table 1). Diagnoses 
were made based on the National Institute on Aging/Reagan Institute of the Alzheimer 
Association (NIA-Reagan) Consensus Recommendations for the postmortem 
diagnosis of AD. Particularly, tissues were evaluated for their ABC scores (Aβ deposit 
score, Braak neurofibrilliary tangles stage and CERAD neuritic plaque score), 
illustrating the level of AD neuropathologic change.  
 
 
Table 1. Characteristics of human brain tissue. Samples were derived from post 
mortem control, Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD) cases 
with PMI maximum 4 hours. Mean age patients with MCI were higher compared to 
control or AD patients, which generate a significant difference between MCI and AD 
groups. There was no significant difference in sex or PMI between the groups. For 
ApoE genotype, the most common genotype is listed. ANOVA or Chi2 test were used 
for group comparisons analysis. According to AD pathogenesis and clinic, AD patients 
Features Control MCI AD 
Range Mean (SD) Range Mean (SD) Range Mean (SD) 
Age (years) 73 – 99 87.4 (8.1) 83 – 99 92.1 (7.2) 66 – 99 84.3 (10.1) 
Number of samples Male Female Male Female Male Female 
17: 13 15 : 15 16: 14 
Post-mortem 
interval/PMI (hour) 
1.5 – 3.8 2.8 (0.70) 1.8 – 3.5 2.7 (0.7) 1.5 – 3.5 2.6 (0.6) 
MMSE 26 - 30 28.5 (1.4) 21 - 30 26.7 (2.5) 0 - 28 11.9 (9.8) 
Braak Stage 1 – 4 2.7 (1.0) 1 - 5 3.2 (1.1) 4 - 6 5.4 (0.7) 
ApoE 3/3 3/3 3/4 
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exhibit significantly declined cognitive performance, progressed further in the Braak 
staging scheme and a higher frequency of ApoE4 alleles. 
 
 
2.3. Solutions 
Recipe 1: Homogenization and gradient buffers for synaptosome isolation (sucrose 
density gradient) 
Buffer solution Final concentration 
Tris acetate 50 mM 
Ethylene diamine tetraacetic acid (EDTA) 1 mM 
Ethylene glycol tetraacetic acid (EGTA) 1 mM 
Sodium pyrophosphate dibasic (Na2H2P2O7) 5 mM 
Sodium fluoride (NaF) 5 mM 
Sodium orthovanadate (Na3VO4) 2 mM 
4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) 1 mM 
Protein Inhibitor Cocktail (PIC) 0.2% V/V 
pH 7.4 
 
Final Buffers Preparation 
Homogenization buffer 0,32 M Sucrose in buffer solution 
Gradient buffer 1 1,40 M Sucrose in buffer solution 
Gradient buffer 2 1,00 M Sucrose in buffer solution 
 
 
Recipe 2: Homogenization buffer for whole brain isolation 
 Final concentration 
Dulbecco’s Phosphate Buffered Saline (PBS) 10x 
Sodium fluoride (NaF) 5 mM 
Sodium pyrophosphate dibasic (Na2H2P2O7) 20 mM 
4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) 1 mM 
Sodium Dodecyl Sulfate (SDS) 2% 
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Recipe 3: RIPA lysis buffer (RadioImmunoPrecipitation Assay) 
 Final concentration 
Tris (hydroxymethyl) aminomethane pH 7.2 50 mM 
Sodium chloride (NaCl) 150 mM 
Nonidet-P-40 (NP-40) 2 % 
Sodium Deoxycholate (NaDOC) 1 % 
Sodium Dodecyl Sulfate (SDS) 0.2 % 
 
 
Recipe 4: Running buffer for western blot 
 Final concentration 
MES running Buffer (20X) 50 mL 
ddH2O 950 mL 
Total 1000 mL 
 
 
Recipe 5: Transfer buffer for western blot 
 Final concentration 
NuPAGE™ Transfer Buffer (20X) 50 mL 
70% ethanol 285 mL 
ddH2O 665 mL 
Total 1000 mL 
 
 
Recipe 6: Tris-buffered saline (with Tween 20) TBS (T) for washing the blot 
membranes and antibody solutions (first and second) 
 Final concentration 
Tris (hydroxymethyl) aminomethane 20 mM 
NaCl 150 mM 
Tween 20 0.1% 
 
 
 
  28 
Receipe 7: Blocking buffer for western blot 
 Final concentration 
Tris (hydroxymethyl) aminomethane 20 mM 
NaCl 150 mM 
Tween 20 0.1% 
Bovine serum albumin (BSA) 3% 
 
 
Recipe 8: C18 spin columns activation solution 
 Final concentration 
LC/MS grade methanol (or ACN) 200 mL 
Water for HPLC 200 mL 
Total (per sample) 400 mL 
 
 
Recipe 9: C18 spin columns equilibration and wash solution 
 Final concentration 
Trifluoroacetic acid (TFA) 0.5% 
LC/MS grade acetonitrile (ACN) 5% 
Water for HPLC to 400 mL 
Total (per sample) 400 mL 
 
 
Recipe 10: C18 spin columns sample buffer 
 Final concentration 
Trifluoroacetic acid (TFA) 2% 
LC/MS grade acetonitrile (ACN) 20% 
Water for HPLC adjusted to end volume 
Adding 1μL for every 3μL of sample 
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Recipe 11: C18 spin columns elution solution 
 Final concentration 
LC/MS grade acetonitrile (ACN) 70% 
Water for HPLC adjusted to end volume 
Total (per sample) 40 mL 
 
 
2.4. Isolation of synaptosomes 
Synaptosomes were prepared from fresh mouse and human brains. 
Approximately 200 mg tissue was used with equal amounts of gray and white matter. 
Tissues were then homogenized (9 volumes of buffer per tissue weight) in 0.32 M 
sucrose buffer (50 mM Tris-acetate, 5 mM disodium pyrophosphate, 1 mM EDTA, 1 
mM EGTA, 2 mM Na3VO4, 5 mM NaF, 1 mM AEBSF, 1:500 diluted cOmplete 
protease inhibitor cocktail, pH 7.4). Homogenization was performed manually using 
15 up and down strokes using a glass homogenizer with a Teflon pestle (0.1 to 0.15 
mm clearance). Nuclei and cellular debris were removed by centrifugation at 800 g for 
5 minutes at 4 °C. The collected supernatant was transferred slowly on top of a 
discontinuous sucrose gradient consisting of 1.0 M and 1.4 M sucrose buffer. MLS-50 
swinging bucket rotor (Beckman, Krefeld, Germany) was used to perform gradient 
centrifugation at 54000 g for 90 minutes at 4 °C. The synaptosomal fraction was 
collected from the interface between 1.0 M and 1.4 M sucrose layers. The resultant 
fraction was diluted with 4-fold volume of HPLC-grade water and sedimented at 54000 
g for 15 minutes at 4 °C. The supernatant was taken out and the synaptosomal pellet 
was stored at −80°C immediately.  
 
 
2.5. BCA protein assay 
A commercial BCA protein assay kit (colorimetric based) from Thermo Scientific 
PierceTM was used to estimate the protein concentration. The assay procedure was 
performed as described by the manufacturer. BCA Reagent A (sodium carbonate, 
sodium bicarbonate, BCA and sodium tartrate in 0.1 M sodium hydroxide) and reagent 
B (4% cupric sulphate) are stable at room temperature (Thermo Fisher Scientific). 
Standard working reagent (SWR) was freshly prepared before use by adding 100 
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volumes of Reagent A with 2 volumes of Reagent B (ratio 50:1). The mix solution color 
is apple green. Following the standard assay procedure, BSA 2 mg/ml is used as a 
standard with 5 working standards (1–5 μg). After incubation at 37°C for 30 min, the 
absorbance was measured at 562 nm against a reagent blank using a microplate 
reader (Beckman Coulter Co.). The samples concentration was measured with 
reference to standards. 
 
 
2.6. Protein detection by western blot 
Following the determination of protein concentrations using the BCA Protein 
Assay kit, the pellets were resuspended in on RIPA buffer (25mM Tris, 150mM NaCl, 
1% NP40, 0.5% NaDOC, 0.1% SDS, pH 7.2). 3-month-old WT mice and healthy 
control human samples (n=3 each) were used for brain tissue homogenates extracted 
in RIPA buffer. Equal amounts of protein samples (20 μg) were separated by 4-12% 
NuPAGE (Invitrogen) using MES buffer and transferred to the nitrocellulose 
membranes.  
 
Membranes were blocked for 1 hour at room temperature (RT) in 3% BSA in 
TBS containing 0.01% Tween 20 (TBS-T), followed by incubation at 4°C overnight with 
primary antibodies in TBS-T (Table 2). After washing with TBS-T, the membranes 
were incubated in the appropriate dye labeled secondary antibodies (Li-Cor 
Biosciences) in 3% BSA on TBS-T for 1 hour. Immunolabeled proteins were imaged 
using Odyssey Infrared Scanner (Li-Cor Biosciences).  
  
Target (protein) Host Concentration Manufacturer 
Glutamate receptor 1 
(GluR1) 
Rabbit 1:1000 Millipore, ab1504 
Lamin B1 Mouse 1:500 Proteintech, 66095-1-Ig 
NMDA receptor 2B 
(NMDAR2B) 
Rabbit 1:1000 Millipore, ab1557p 
Post-synaptic density 
(PSD95) 
Mouse 1:2000 
Thermo Fisher Scientific, 
MA1-064 
Synaptophysin Rabbit 1:1000 Abcam, ab52636 
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Tubulin Mouse 1:2000 
Thermo Fisher Scientific, 
62204 
 
Table 2. Immunoblot analysis of synaptosomal proteins. Synaptosomes and whole 
brain tissue homogenate of 3-month-old wild type mice and healthy control human 
samples were analyzed by western blot. The pre- and post-synaptic protein markers 
were evaluated consists of synaptophysin, NMDAR2B, GluR1 and PSD95. Lamin B1 
was used as nuclear marker and alpha tubulin as a loading control.  
 
 
2.7. Electron microscope 
The synaptosome samples were fixed at 4 h at 4°C in modified Karnovsky's 
fixative (2.5% glutaraldehyde in 0.1 M cacodylate buffer + 2% paraformaldehyde +4 
mM CaCl2, pH 7.35). After the sample had been washed in 0.1 M cacodylate buffer 
for 2 h, it was post-fixed in 1% OsO4 in cacodylate buffer containing 15 mg per mL 
potassium ferrocyanide for 1 h at 20°C in the dark. The post-fixed sample was then 
washed for 5 min to remove unreacted OsO4, dehydrated gradually in ethanol (two 
changes 50% ethanol, two changes 70% ethanol, two changes 95% ethanol, four 
changes 100% ethanol) and embedded in Epon 812 that was left to polymerize at 
60°C for 3.5 d. Finally, it was post-stained with 5% uranylacetate for 30 min and lead 
citrate for 7 min. 
 
 
2.8. Internal standard 
An internal standard was used as a quality control measure for all sixplex 
analyses. It was also used to identify data that do not meet quality criteria. For this 
purpose, Pearson correlation coefficient was done across all internal standards on 
both mouse and human samples. It measures the linear correlation between the 
samples and has a value between +1 (positive correlation) and -1 (negative 
correlation). Ideally the Pearson correlation value should be near to +1 on all of the 
internal standards comparison, which implies that the qualities of the samples are 
comparable. In this study, the internal standard was pooled from representative equal 
amounts (50 µg) of all synaptosome samples used in the experiment, aliquoted, and 
labeled with the iodoTMTTM 126 label of the sixplex. IodoTMTTM 126 was chosen as 
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the labeling reagent with no specific reason. Internal standard was added at the 
beginning of the sample work-up and treated equally as other synaptosome samples. 
 
 
2.9. IodoTMT workflow for synaptosomal proteins  
2.9.1. Protein labeling with iodoTMT 
Synaptosome pellets were reconstituted in 1 μg μl
-1 
HENS lysis buffer 
containing 100 mM HEPES (pH 7.8), 1 mM EDTA, 0.1 mM Neocuproine, and 1% SDS 
from Thermo Fisher Scientific. Equal amount of proteins (50 μg) from each 
synaptosome sample was individually labeled with iodoTMT sixplex labeling reagent. 
Followed by digestion, peptides clean up (detergent and salt), enrichment, and MS 
analysis. MMTS (20 mM final concentration, dissolved in dimethyl formamide) was 
added to prevent rearrangements of thiol-modifying groups and incubated for 30 min 
at room temperature with repeated vortexing (protected from light). The MMTS excess 
was discarded by acetone precipitation stored at -20 °C for 1 h. The pellets were 
dissolved in 50 μL of HENS buffer and nitrosothiol groups were reduced by 1 μl of 1 
M sodium ascorbate (diluted in water). Each sample was directly labeled with 1 μL of 
iodoTMT labeling reagent (each 0.2 mg iotoTMT reagent was solubilized with 10 μl of 
LC/MS grade methanol). Allow the reaction to proceed for 1 hour at 37 °C in the dark, 
then quenched with 0.5 M dithiothreitol (20 mM final concentration) for 15 minutes at 
37 °C to remove excess iodoTMT reagents. Six different samples (labeled with 
iodoTMTTM 126-131) were mixed and alkylated with 10 μl of 0.5 M iodoacetamide in 
300 μl of HENS buffer incubated for 1 hour at 37 °C.  
 
 
2.9.2. Tryptic digestion and peptide desalting 
Alkylated samples were then precipitated with acetone precipitation. The 
precipitate was dissolved in 50 mM ammonium bicarbonate buffer, pH 8 for overnight 
digestion at 37 °C with trypsin (protein : trypsin ratio = 1:40 w/w). After digestion, the 
peptides were acidified using 10% trifluoroacetic acid (TFA) to a final concentration of 
0.5% and desalted using C18 spin columns (Thermo Fisher Scientific). C18 spin 
column was prepared for peptides clean up by rinsing the spin column with 200 µl 
activation solution, repeated twice and followed with equilibration solution (repeated 
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twice). Sample was then loaded on top of the resin and flow-through was reloaded to 
ensure complete binding. After washing with wash solution (0.5% TFA in 5% ACN), 
the elution was done with 70% (v/v) acetonitrile (ACN), dried and dissolved in 100 μL 
TBS buffer, pH 8.0 (50 mM Tris, 150 M NaCl).  
 
 
2.9.3. Enrichment of iodoTMT-labeled peptides 
For peptide enrichment, the samples were incubated with 30 μl immobi lized 
Anti-TMTTM Resin  at room temperature for 2.5 hours with gentle end-over-end 
rotation. The resin was washed using 100 μl TBS (three times) then subsequently with 
100 μl HPLC-grade water (three times). The peptides that bound to the resin were 
eluted twice with 30 μl TMT elution buffer (Thermo Fisher Scientific). The pooled 
eluates were dried using vacuum centrifugation and resuspended in 8 μl of 0.1% TFA 
for nanoHPLC MS/MS analysis.  
 
 
2.9.4. LC-Mass spectrometry analysis 
The solution was injected onto a C18 trap column (100 μm inner diameter, 20 
mm length, ReproSil-Pur 120 C18-AQ, Dr. Maisch, Ammerbuch, Germany) packed in-
house. Solvent A was 0.1% formic acid (FA), solvent B was 90% ACN, 0.1% FA. The 
peptides were eluted from trap column onto a C18 analytical column (75 μm inner 
diameter, 200 mm length, ReproSil-Pur 120 C18-AQ, 1,9 µm, Dr. Maisch, 
Ammerbuch, Germany). Peptides were separated during a linear gradient from 4% to 
35% solvent B within 240 min at a flow rate of 300 nl/min. The nanoHPLC was coupled 
online to an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, 
Bremen, Germany). Ions between 330 and 1700 m/z were scanned in the Orbitrap 
detector with a resolution of 30,000 (maximum fill time 400 ms, AGC target 106). The 
twenty most intense precursor ions with threshold intensity of 5000 were subjected to 
higher energy collision induced dissociation (HCD). Fragment ions were then analyzed 
in the Orbitrap. Fragmented peptide ions were omitted from repeated analysis for a 
period of 15 s.  
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2.10. Data analysis and protein identification 
Data processing and analyses were performed using Proteome DiscovererTM 
software 2.1.0.81 from Thermo Fisher Scientific. Peptide identification was identified 
with in-house Mascot server, version 2.5.1 (Matrix Science Ltd, London, UK). MS/MS 
data (inclusive a-series ions) were matched against mouse / human sequences from 
SwissProt (release 2015_04). Up to two missed cleavages were allowed for tryptic 
peptides. Low scoring spectrum matches were re-analyzed with semi tryptic specificity 
with one missed cleavage. Carbamidomethylation (Cys), acetylation (protein N-
terminus), Oxidation (Met), and iodoTMTTM sixplex (on Cys) were included as dynamic 
modifications. Mascot results from searches against SwissProt were evaluated using 
percolator algorithm (version 2.05) as implemented in Proteome Discoverer. A 
posterior error probability of 1% or better was used to identify the resulting peptides. 
Precursor ion m/z tolerance of 10 ppm and a fragment ion tolerance of 20 mmu were 
allowed. Due to the experimental design, proteins were reported with at least one 
matching peptide: In cases that only one site is nitrosylated in a protein, only one 
labeled peptide can be identified after enrichment.  
 
The biological replicates are combined into one table, which consists of all 
peptides in the rows and all the groups/conditions of replicates in the columns. The 
table is filled with intensities. Before applying the statistics, the table is filtered by 
excluding the peptides that occur only in one or two replicates. The intensities were 
then log2 transformed, median normalized and compared pairwise between replicates 
from which the Pearson correlation coefficient is computed for the internal standard 
(iodoTMTTM 126 labeled). The pooled sample of internal standard was excluded when 
the Pearson’s data was below 0.5 (Hinkle et al., 2003; Mukaka, 2012). After the 
exclusion, pairwise tests on mice data were performed where each group was 
compared across age (3-month vs 12-month-old) and genotype. Whilst on human 
results, pairwise tests were performed where MCI and AD were compared to control 
patient. To minimize false positive results, the peptides identified in less than 50% of 
the total biological replicates were omitted (Blonder and Veenstra, 2007; Kuster et al., 
2005; Mallick et al., 2007).  
 
The statistical methods used in this study were the combination of Limma, Rank 
Product and bootstrap analysis. After peptide exclusion, normalized TMT tag reporter 
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ion intensities were used to calculate fold change using linear model-based (limma) 
and ranks (RankProd) (Schwammle et al., 2013). Raw intensities were transformed to 
log2 (fold change) values. P-values were calculated for each peptide and adjusted for 
multiple testing using Benjamini and Hochberg approach to control false discovery 
rates. To evaluate if the initial fold change is representative of the population, bootstrap 
analysis was calculated (Mukherjee et al., 2003b; Wang et al., 2012; Zhang et al., 
2016b). Data table (consist of eight conditions for mouse and three for human study) 
was created with randomly chosen replicates. The bootstrap or random principle is 
drawing with replacement to generate the null hypothesis to which the actual data 
were compared (Barbash and Sakmar, 2017). Thus the same replicate can occur more 
than once in the data table with the same or different conditions. Bootstrapping with 
10000 repetitions was used to calculate the confidence interval (CI). The 95% 
confidence interval of all the 10000 log2 fold changes was calculated for each peptide. 
The initial calculated log2 fold change was further analyzed to see if the peptide lies 
within this CI or not. This represents if the initial fold change is a good representation 
of the population (stated “yes” on the table) or not (“no”). 
 
The criteria for inclusion of a peptide in the mouse groups was the same as that 
used for human: a protein/peptide was considered significant at a fold-change of more 
than 1.2-fold (log2  ± 0.263) and p < 0.05 level using adjusted p-values (q-value_limma 
and/or q-value_RP) or it lays on 95% confidence interval (CI) of bootstrap analysis. 
Proteins were reported even with one unique peptide due to the experimental design 
using peptides enrichment. Volcano plots were used to visualize the data; log2 fold 
change of each SNO-Cys protein was plotted against –log2 adjusted p-value. 
Increased and decreased SNO proteins were identified in mouse and human 
synaptosomal samples, which defined as positive and negative fold change ratios in 
the pairwise group comparison. The identified proteins were annotated using 
Uniprot/SwissProt database (Bateman et al., 2015) then classified using Panther 
Gene Ontology (GO)  (Thomas et al., 2003) and Gorilla search engine (Eden et al., 
2009).
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3. Results 
3.1. Synaptosome isolations analysis 
Various techniques of synaptosome isolation have been established using 
different centrifugation and buffer reagents, such as sucrose, Ficoll/sucrose or Percoll 
density gradient centrifugation, all of which result in purifying a crude synaptosome 
fraction from the contamination (Jaffrey and Snyder, 2001). This study used 
conventional sucrose density gradient to isolate synaptosomal proteins from mouse 
and human brain tissues. The yield of the proteins obtained from the purified 
synaptosomes using sucrose density gradient were scarce but it was comparable 
between mouse and human samples (3.0 ± 1.0 µg/mg and 2.8 ± 0.8 µg/mg of brain 
tissue, respectively). 
 
The purity of synaptosome isolations was further confirmed by electron 
microscopy (Figure 5) and western blot analyses of 3-month-old WT and healthy 
control human samples using antibodies specific for synaptic and nuclear markers 
(Figure 6).  
 
 
Figure 5. Exemplary image of a synaptosome fraction showing presynaptic terminal 
including synaptic vesicle and mitochondria, along with postsynaptic membrane. The 
picture was taken by transmission electron microscopy using a chemical fixation 
(Sosinsky et al., 2008). Sample taken from the synaptosome isolation of a 3-month-
old wild type mouse. 
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Enrichment of pre- and post-synaptic proteins was determined using western 
blotting against synaptophysin, NMDAR2B, GluR1 and PSD95 markers in the 
synaptosomal fraction compared to brain tissue homogenates. In contrast, level of the 
nuclear marker Lamin B1 was decreased in the synaptosomal fraction. Alpha tubulin 
was used as loading control.  
 
 
 
Figure 6. Representative immunoblot analysis of synaptosomal proteins isolated from 
3-month-old wild type mouse and healthy control human samples. Compared to the 
whole brain tissue homogenate, the synaptosomal fraction contained higher levels of 
synaptophysin (~38 kDa), NMDAR2B (~166 kDa), GluR1 (~100 kDa) and PSD95 (~95 
kDa) relative to 20 µg brain tissue homogenates. While the whole brain tissue 
homogenate showed higher expression of the nuclear marker lamin B1 (~66 kDa). 
Alpha tubulin was used as a loading control. Equal amounts of protein from whole 
brain tissue homogenates and synaptosomal fractions were loaded in electrophoresis 
gels. 
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3.2. Proteome analysis of synaptosomal proteins 
The composition of the SNO-proteome was analyzed using 
Gene Ontology enRIchment analysis and visuaLiAtion (Gorilla) search engine (Eden 
et al., 2009) and Uniprot/SwissProt based on the localization classification (Bateman 
et al., 2015). The Gorilla search engine result (illustrated in Figure 7) indicates 
enriched GO terms in the cellular components of organelle membrane (GO:0031090), 
oxidoreductase complex (GO:1990204), cytoplasmic part (GO:0044444), organelle 
inner membrane (GO:0019866), intracellular organelle (GO:0043229), intracellular 
membrane bounded organelle (GO:0043231) and components of mitochondrial 
(GO:0044429; GO:0005739; GO:0031966; GO:0044455; GO:0005743). Definitions of 
the specific components are available from the Gene Ontology Consortium 
(http://www.geneontology.org/) database. This result revealed the enrichment of 
synaptosome components such as cytoplasmic part, cell membrane and mitochondria 
that are enriched in the presynaptic terminal (Swomley et al., 2014). 
 
Figure 7. Classification of identified synaptosomal proteins based on cellular 
localization (Wijasa et al., 2017). Reproduced from “Proteome profiling of s-
nitrosylated synaptosomal proteins by isobaric mass tags”, by T. S. Wijasa et al., 2017, 
Journal of Neuroscience Methods, 291, p. 95-100. Copyright 2017 by Elsevier B. V. 
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3.3. Method establishment 
Proper sample preparation for MS-based analysis is an important step in 
proteomic workflow, which can influence MS results directly (Gundry et al., 2009). In 
the initial testing (Table 3), the focus was on three alternative approaches for SNO-
quantitation: the widespread used BST, 2D-DIGE with a modified labeling procedure 
(NitroDIGE) and SNO isobaric mass tags labeling (iodoTMTTM). In the first round of 
method adaptation, the degree of biotinylation (representing S-nitrosylation) in the 
BST was determined by anti-biotin immunoblotting, streptavidin pull-down followed by 
immunoblotting and MS based identification of biotinylated peptides. Although BST is 
frequently used, this method has a relatively low-throughput and the biotinylated 
peptides hinder the localization of the SNO-Cys modification sites (Qu et al., 2014a). 
Approximately 4193 unique peptides were identified representing 509 proteins of 
which approx. 6% were biotinylated on cysteines after the enrichment step. 
Additionally, when applying the BST approach for SNO labeling, the quantitation still 
has to be done with additional labels or label-free. The NitroDIGE approach enables 
multi-group analysis of protein S-nitrosylation and differentiates changes of modified 
proteins under various conditions. No difference was found between the 2D-DIGE 
spots of unlabeled synaptosome sample compared to the CyDyeTM-labeled 
synaptosome sample (quantified by SameSpots). Low endogenous S-nitrosylation 
proteins may be one of the reasons for this unsuccessful transfer method. Among 
these, labeling with isobaric mass tags (iodoTMTTM sixplex Thermo Fisher 
Scientific™, USA) provided the most promising results, both in mice and human brain 
samples. This protocol has the advantage of using one label for enrichment, 
identification, and multiplex quantitation of modified proteins/peptides. It enables the 
identification of endogenous SNO-proteins/pepties without NO donor for nitrosylation. 
The enriched and identified proteins/peptides were in line with previous reports on 
synaptosomal proteomics. 
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Methods Principles 
Advantages (+), drawbacks (-), 
performance on synaptosome sample 
1D electrophoresis 
(1DE) and 
immunodetection 
[rieder] 
SNO proteins determined by an 
anti S-nitrosocysteine antibody, 
with the rationale to identify bands 
containing SNO proteins for 
following mass spec-based 
analysis 
+ Straightforward approach 
+ Enrichment possible when 
combined with Anti-SNO-IP 
− Poor resolution of proteins 
− No stable labeling of the SNO 
site 
2D electrophoresis 
(IP-2DE) and 
immunodetection 
[rieder] 
anti S-nitrosocysteine antibody 
used to immunoprecipate SNO 
proteins followed by 2D 
electrophoresis 
+ Resolution improved by 2D-
separation of proteins 
+ Enrichment possible when 
combined with Anti-SNO-IP 
− No stable labeling of the SNO 
site 
• <10 spots detected with up to 
150 µg of starting material  
NitroDIGE [Qu 
nitrodige] 
Modified biotin switch technique 
(BST) using fluorescence-tagged 
CyDyeTM thiol reactive agents 
(labeling of SNO-Cys with 
CyDyeTM) in combination with 2D 
DIGE.  
+ Low amount of starting material 
required (50 µg) 
+ Quantitative label on SNO site 
+ Multiplex (2-plex) 
− Protein resolution improved over 
other gel based approaches, but 
lower compared to MS based 
techniques 
+ Unsuccessful method transfer: 
No difference between 2DE 
spots of unlabeled compared to 
CyDyeTM-labeled synaptosome 
sample (quantified by 
SameSpots). Low endogenous 
S-nitrosylation proteins may be 
one of the reason. 
Biotin switch 
technique (BST) 
with enrichment 
[jaffrey] 
Blocking of free thiols (by MMTS), 
reduction of S-nitrosothiols (by 
ascorbate), biotin-labeling of 
previous SNO site. Enrichment of 
peptides by biotin affinity 
purification. 
+ Enrichment of SNO proteins 
+ Stable labeling of SNO site 
+ Frequently used method with 
large number of references 
− After labeling of SNO site, 
quantitation has to be done with 
additional labels or label-free 
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IodoTMTTM switch 
labeling (iodoTMTTM 
sixplex) 
Same principle as BST, with four 
major steps: 1st, free thiols 
blocking (MMTS), 2nd, reduction of 
S-nitrosothiols (ascorbate), 3rd, 
iodoTMT labeling 4th, affinity 
enrichment using anti-TMTTM 
resin 
• Low amount of starting material 
was sufficient (50 µg) 
• Quantitative label on SNO site 
• Multiplex (ICAT: 2-plex; 
IodoTMTTM: 6-plex) 
• Successful adaption with 
minimal amount of optimization 
• High yield and enrichment of 
SNO peptides 
 
Table 3. Proteomic methods for SNO protein quantification. Various quantitative 
methods have been developed, which classified into two categories, gel-based and 
gel-free MS-based proteomics. This table provides an overview of the different 
methods tested in this study for their applicability on synaptosome samples. 
 
 
3.4. Proteome comparisons of synaptosomal proteins 
Subcellular localization generated from Uniprot/SwissProt displayed 
comparable enrichments of common synaptosome components between the 
unlabeled synaptosome (Figure 8A), the IodoTMT labeled SNO synaptosome (Figure 
8B) and published results by Engman et al. (Engmann et al., 2010) on regular peptide 
N-terminal TMT labeling of synaptosome (Figure 8C). Results in figure 8A and 8B 
were both acquired from the synaptosome isolation protocol on Heneka’s laboratory 
(chapter 2.3) (Wijasa et al., 2017). The SNO-proteome of synaptosome (iodoTMT-
labeled) contained 30% mitochondrial proteins (Fig. 8B). Furthermore, high fractions 
of cytoplasmic (25%), cell membrane (20%) and synapse-associated proteins (6–8%) 
were found, which is in alignment with the expected composition of synaptosomes 
(see discussion). The localization of the identified synaptosomal proteins/peptides 
between unlabeled, and labeled synaptosome (iodoTMT or TMT) displays similar 
enrichment results with a majority of cytoplasm 24–28%, mitochondria 24–34%, cell 
membrane 14–22%, and synapse 6–11%. Small amount of endoplasmic reticulum 
and nuclear associated proteins were also found, due to similar density as 
synaptosomes. 
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Figure 8. Cellular localization of mouse synaptosome (Wijasa et al., 2017). 
Reproduced from “Proteome profiling of s-nitrosylated synaptosomal proteins by 
isobaric mass tags”, by T. S. Wijasa et al., 2017, Journal of Neuroscience Methods, 
291, p. 95-100. Copyright 2017 by Elsevier B. V. 
 
 
The subcellular localization analyzed from different variants of synaptosome 
preparation and labeling combinations was compared. In the murine synaptosome 
samples, the results using iodoTMT protocol are comparable or higher than those 
described in published publications on synaptosome samples. As example: BST 
analysis on SNOSID (SNO side identification) identified 138 SNO proteins (Zareba-
Koziol et al., 2014) of which 85% were found overlapping with this study’s results 
(Figure 8F) and 240 proteins were identified using TMT (Tandem Mass Tag) (Figure 
8E) both on synaptosome samples. The composition of the detected proteome was 
consistent with prior publications on the synaptosome proteome, which were labeled 
with TMT-independent of their modifications (Figure 8C) (Engmann et al., 2010) and 
with BST on SNOSID (Figure 8D) (Zareba-Koziol et al., 2014). The SNO-proteome of 
synaptosome contained more than 30% mitochondrial proteins in all labeling 
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procedures (iodoTMT-labeled, TMT-labeled and Biotin Switch Technique; Figure 8B-
D), presumably derived from the large numbers of mitochondria located in synapses. 
 
 
3.5. IodoTMT and mass spectrometry (MS)-based method performance 
The MS-based method using iodoTMT labeling and enrichment was first tested 
using wild type mouse samples (n = 3) and further extended to human brain samples 
(n = 2) from donors without CNS disorders. This is done to confirm that the entire 
procedure performs well in animal and human brain samples. To ensure the 
consistency and reliability of the analyzed data sets, a comprehensive internal quality 
control procedure has been implemented. Which is done by analyzing the intensity of 
reporter ions and calculating the inter-sample variances from the internal standard. 
The internal standard consisted of all samples used in the experiment; it was pooled, 
labeled and measured in all runs with iodoTMT126 label reagent. A representative 
MS/MS spectrum is depicted in Figure 9 showing intense reporter ions and a clear b- 
and y-series of selected fragment ions.  
 
 
 
Figure 9. A representative MS/MS spectrum of the iodoTMT-labeled peptide 
SICDTSNFSDYIR derived from ubiquitin-like modifier-activating enzyme 1, which 
shows intense reporter ions and b- and y-series of selected fragment ions (Wijasa et 
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al., 2017). The 6 reporter ion peaks are shown in the enlarged section of the lower 
mass range. Reproduced from “Proteome profiling of s-nitrosylated synaptosomal 
proteins by isobaric mass tags”, by T. S. Wijasa et al., 2017, Journal of Neuroscience 
Methods, 291, p. 95-100. Copyright 2017 by Elsevier B. V. 
 
 
To analyze the overall method variance including preparative pipetting, sample 
preparation, digestion, IodoTMTTM labeling, IodoTMTTM enrichment until pooling and 
analysis of the samples, reporter ion intensities of all identified peptides were 
compared over all 6 labels (in the same-same-experiment). The average variance 
between single reporter ion channels and the mean of all channels was 20%. 
Theoretically, all identified peptides should be linked to a TMTTM label on a previously 
nitrosylated cysteine. In this study, around 72% of identified peptides contained at 
least one cysteine, of which 93%-98% were IodoTMTTM labeled. In conclusion, the 
cysteine-targeted labeling was highly specific, whereas the anti-TMT-antibody-based 
enrichment and purification approach left around 28% of unlabeled peptides. 
Unspecific TMT-labeling (<1% of peptides) on the peptide N-terminus (the target of 
TMTTM protocol) was hardly found. Essentially, the identification of nitrosylated 
peptides from synaptosome samples was not possible without prior labeling or an 
enrichment approach.  
 
 
3.6. Peptides exclusion 
For MS quality control, Pearson correlation coefficient was done across all 
internal standards (iodoTMTTM 126 labeled) on both mouse and human samples. 
Samples were excluded from further analysis if the Pearson correlation score was 
below 0.5 or moderate correlation (Figure 10) (Hinkle et al., 2003; Mukaka, 2012). 
After the exclusion, the study ended up with 60% of the mice samples (n = 12/group 
from n = 20/group) and 67% of the human samples (n = 20/group from n = 30/group), 
which were then used for further analysis.  
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Figure 10. Pearson correlation coefficient for MS quality control. Pearson correlation 
coefficient was done for all internal standards which labeled with iodoTMTTM 126 on 
both mouse and human samples. The peptides were excluded from further analysis if 
Pearson correlation score was below 0.5. The study end up with n=12 mice/group and 
n=20 human/group after exclusion. 
 
 
3.7. Statistical analysis of quantitative proteomics data 
Increased and decreased SNO proteins/peptides were identified in mouse and 
human synaptosomal samples. The fold-change threshold was set to 1.2-fold and 
above based on the value frequently used in data analysis of iodoTMT (Chang et al., 
2016; Wojdyla et al., 2016; Yao et al., 2015). The total number of identified synapto-
SNO peptides or proteins based on pairwise groups comparison are shown in table 4, 
5 and 6. Statistical analysis and magnitude of the response (fold change) were 
adopted to select meaningful proteins from total identified proteins. The fold change 
values in human samples were not as high as in mouse samples. Generally, the total 
numbers of increased SNO proteins/peptides in pairwise group comparisons were 
higher using bootstrap analysis compared to Limma and RankProduct.  
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Table 4. Overview of synapto-SNO peptides at pairwise comparison of mice across age (12-month vs 3-month-old mice). The 
reproducibility among replicates was set to > 50% to minimize false positive results. Hash sign (#) represents significant 
peptides/proteins with fold change ≥ 1.2 fold (log2  ± 0.263) and adjusted p-value < 0.05 (Limma or RankProduct) (Schwammle et 
al., 2013) or it lays on 95% Confidence Interval of bootstrap analysis) (Efron and Tibshirani, 1993).  
 
 
12-month-old mice 
(Genotype effect) 
APP/PS1 - WT APP/PS1 – APP/PS1/NOS2-/-  WT – NOS2-/- 
Increased Decreased Increased Decreased Increased Decreased 
Total peptides 373 429 425 391 433 419 
Total proteins 252 271 263 252 258 259 
Total peptides (n > 50%) 320 374 370 344 376 365 
Total proteins (n > 50%) 224 241 236 231 225 235 
Total peptides (n>50%)#, fold change ≥ 1.2 fold 53 35 49 49 21 89 
Age effect 
WT 12m vs 3m NOS2-/- 12m vs 3m APP/PS1 12m vs 3m APP/PS1/NOS2-/- 12m vs 3m 
Increased Decreased Increased Decreased Increased Decreased Increased Decreased 
Total peptides 423 401 411 377 406 373 367 425 
Total proteins 251 231 243 234 244 220 231 263 
Total peptides (n > 50%) 372 363 369 328 363 341 326 373 
Total proteins (n > 50%) 222 213 222 209 220 209 207 237 
Total peptides (n>50%)#, fold 
change ≥ 1.2 fold 176 150 75 30 130 142 68 51 
Total proteins (n>50%)#, fold 
change ≥ 1.2 fold 101 87 53 22 87 78 58 45 
Significant proteins (Limma and 
RankProduct Vs. Bootstrap) 68 / 94 67 / 61 3 / 53 5 / 20 18 / 87 25 / 78 0 / 58 1 / 44 
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Total proteins (n>50%)#, fold change ≥ 1.2 fold 51 34 45 41 20 70 
Significant proteins (Limma and RankProduct Vs. 
Bootstrap) 1 / 51 0 / 34 0 / 45 0 / 41 1 / 20 1 / 70 
 
Table 5. Overview of synapto-SNO peptides at pairwise comparison of 12-month-old mice across genotype. The reproducibility 
among replicates was set to > 50% to minimize false positive results. Asterisks (#) represents significant peptides/proteins with fold 
change ≥ 1.2 fold (log2  ± 0.263) and adjusted p-value < 0.05 (Limma or RankProduct) (Schwammle et al., 2013) or it lays on 95% 
Confidence Interval of bootstrap analysis) (Efron and Tibshirani, 1993). 
 
 
 MCI - Control AD – MCI AD - Control 
 Increased Decreased Increased Decreased Increased Decreased 
Total peptides 430 439 462 451 446 423 
Total proteins 313 324 330 318 314 298 
Total peptides (n > 50%) 203 165 189 188 220 170 
Total proteins (n > 50%) 163 126 145 146 166 130 
Total peptides (n>50%)#, fold change ≥ 1.2 fold 1 1 20 10 9 2 
Total proteins (n>50%)#, fold change ≥ 1.2 fold 1 1 16 9 9 2 
Significant proteins (Limma and RankProduct Vs. 
Bootstrap) 0 / 1 0 / 1 2 / 15 4 / 9 0 / 9 0 / 2 
 
Table 6. Overview of synapto-SNO peptides at pairwise comparison of human samples during disease development. The 
reproducibility among replicates was set to > 50% to minimize false positive results. Hash sign (#) represents significant 
peptides/proteins with fold change ≥ 1.2 fold (log2  ± 0.263) and adjusted p-value < 0.05 (Limma or RankProduct) (Schwammle et 
al., 2013) or it lays on 95% Confidence Interval of bootstrap analysis) (Efron and Tibshirani, 1993). 
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3.8. Synapto-SNO proteins analyses 
Around 2252 unique peptides were identified in murine synaptosomes 
representing 1064 proteins, of which 33% were identified nitrosylated for the first time. 
While in human synaptosomes, 2134 unique peptides were identified representing 
1097 proteins, of which 69% were identified nitrosylated for the first time (compared 
to the SNO database). Whilst the known published data on the SNO database lists 
2651 peptides (represent 1348 proteins) on murine and 1250 peptides (represent 717 
proteins) on human S-nitrosylated proteome (Lee et al., 2012b) 
 
Since neuroinflammation is thought to represent one of the important factors 
for AD pathogenesis, NOS2 gene was hypothesized to play an important role. The aim 
was to identify the NOS2-dependent SNO proteins in AD and related mouse models. 
In mouse data, multiple group-wise comparisons were performed to determine the 
effect of aging on each genotype group (12-month old compared to young 3-month-
old mice throughout all genotypes) and the effect of the genotype on 12-month-old 
mice. In human data, multiple group-wise comparisons were performed by comparing 
the AD disease progression (control to MCI, MCI to AD and control to AD). There is 
no overlap between up- and down-regulated peptides in all multiple group-wise 
comparisons on mouse and human data. Among the spectrum of regulated proteins, 
only those with an increase of nitrosylation might be correlated to inflammation-
associated activation of NOS2 (see discussion), which were defined by having a 
positive FC ≥ +1.2-fold. 
 
 
3.8.1. Age and genotype effects on S-nitrosylation of synaptic proteins in mouse 
brain. 
To globally visualize the data, log2 fold change of each SNO-Cys protein was 
plotted against –log2 adjusted p-value in a volcano plot. The volcano plots in figure 11 
show synapto-SNO proteins with replicate numbers > 50%, which were altered due to 
the age effect of each genotype. To identify protein levels changes that related to 
physiological aging, wild type 12-month-old mice were compared to 3-month-old mice 
(Figure 11A). After assigning the statistical analysis and setting the magnitude of the 
response to 1.2-fold or higher (log2  ± 0.263) for candidate proteins, a total of 101 
SNO proteins were found to be significantly increased (P < 0.05 or it lays on 95% CI 
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of bootstrap analysis and with FC ≥ 1.2-fold) and 87 SNO proteins decreased. 
Similarly, the comparison of old and young APP/PS1 mice was performed to 
investigate pathological aging (Figure 11C). This yielded 87 increased SNO proteins 
and 78 SNO proteins that were decreased. In order to know which of these SNO 
proteins were differentially regulated during aging in a NOS2-dependent manner, the 
same analysis was repeated to compare the synapto-SNO proteome between old and 
young mice of NOS2-/- and APP/PS1/NOS2-/- background (Figure 11B, D). The age 
comparison of NOS2-/- mice, yielded 53 SNO proteins that were increased 
significantly and 22 SNO proteins that were decreased. While in the APP/PS1/NOS2-
/- mice, 58 SNO proteins were significantly increased and 45 SNO proteins were 
decreased.  
 
The candidate proteins were shown in different colors. The red points indicate 
significant proteins with p-value < 0.05 (Limma or RankProduct) (Schwammle et al., 
2013), within 95% Confidence Interval of bootstrap analysis (Efron and Tibshirani, 
1993) and have a fold change of ≥ 1.2 fold (log2  ± 0.263). The green points specify 
significant proteins calculated using the p-value from Limma and RankProduct and 
have a fold change of ≥ 1.2 fold. The blue points show proteins within 95% Confidence 
Interval of bootstrap analysis and have a fold change of ≥ 1.2 fold (log2  ± 0.263). 
While the gray points indicate proteins without any differences (p-value > 0.05, not 
within 95% Confidence Interval of bootstrap analysis and have a fold change of < 1.2 
fold). Candidate proteins were chosen from red, green and blue points. 
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Figure 11. Volcano plot of synaptosome proteome displaying age effect on protein 
levels for each genotype. Negative log2 p-values (adjusted) were plotted against log2 
protein fold change. Increased protein levels were shown on the positive x-axis, and 
decreased levels were shown on the negative x-axis. The red points show candidates 
with p-value < 0.05 (Limma or RankProduct) (Schwammle et al., 2013), within 95% 
Confidence Interval of bootstrap analysis (Efron and Tibshirani, 1993) and have a fold 
change of ≥ 1.2 fold (log2  ± 0.263). The green points show candidates with p-value < 
0.05, not within 95% confidence interval of bootstrap analysis and have a fold change 
of ≥ 1.2 fold (log2  ± 0.263). The blue points show candidates with p-value > 0.05, 
within 95% confidence interval of bootstrap analysis and have a fold change of ≥ 1.2 
fold (log2  ± 0.263). The gray points show candidates with p-value > 0.05, not within 
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95% confidence interval of bootstrap analysis and have a fold change of < 1.2 fold 
(log2  ± 0.263). The experimental groups were 3-month and 12-month-old wild type 
(WT), NOS2-/- (NOS2 knockout mice), APP/PS1 (transgenic mice carrying the human 
APP and presenilin1 gene) and APP/PS1/NOS2-/- (transgenic mice carrying the 
human APP, presenilin1 gene and are NOS2 knockout mice). (A) Aged WT with 
replicates > 50%. (B) Aged NOS2-/- with replicates > 50%. (C) Aged APP/PS1 with 
replicates > 50%. (D) Aged APP/PS1/NOS2-/- with replicates > 50%. 
 
 
To identify the effect of NOS2 gene deletion on WT control and APP/PS1 of 12-
month-old mice (genotype effect), three pairwise group comparisons were made. 
Figure 12 shows the volcano plots of S-nitrosylation on synaptosomal proteins with 
replicate numbers > 50%, which were altered due to the genotype effect of 12-month-
old mice. The statistical analysis and magnitude of the response (1.2-fold or higher; 
log2  ± 0.263) were assigned for significant proteins. 20 SNO proteins were found 
elevated in WT compared to NOS2-/- samples, 45 SNO proteins on APP/PS1 
compared to APP/PS1/NOS2-/- samples and 51 SNO proteins on APP/PS1 compared 
to WT samples. Aligned with 70 SNO proteins that were significantly decreased in WT 
compared to NOS2-/- samples, 41 SNO proteins on APP/PS1 compared to 
APP/PS1/NOS2-/- samples, 34 SNO proteins on APP/PS1 compared to WT samples. 
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Figure 12. Volcano plot of synaptosome proteome displaying the genotype effect on 
protein levels in the 12-month-old group. Negative log2 p-values (adjusted) were 
plotted against log2 protein fold change. Increased protein levels are shown on the 
positive x-axis, and decreased levels are shown on the negative x-axis. The red points 
show candidates with p-value < 0.05 (Limma or RankProduct) (Schwammle et al., 
2013), within 95% Confidence Interval of bootstrap analysis (Efron and Tibshirani, 
1993) and have a fold change of ≥ 1.2 fold (log2  ± 0.263). The green points show 
candidates with p-value < 0.05, not within 95% confidence interval of bootstrap 
analysis and have a fold change of ≥ 1.2 fold (log2  ± 0.263). The blue points show 
candidates with p-value > 0.05, within 95% confidence interval of bootstrap analysis 
and have a fold change of ≥ 1.2 fold (log2  ± 0.263). The gray points show candidates 
with p-value > 0.05, not within 95% confidence interval of bootstrap analysis and have 
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a fold change of < 1.2 fold (log2  ± 0.263). The experimental groups were 12-month-
old wild type (WT), NOS2-/-, APP/PS1 and APP/PS1/NOS2-/-. (A) APP/PS1 – WT (12 
months old) with replicates > 50%. (B) WT – NOS2-/- (12 months old) with replicates 
> 50%. (C) APP/PS1 – APP/PS1/NOS2-/- (12 months old) with replicates > 50%.  
 
 
To visualize the influence of age, Venn diagrams were made to identify the 
SNO proteins that were differentially regulated only in 12-month-old APP/PS1 mice in 
a NOS2-dependent manner. The age effect on WT animals was set as a control, 
showing an increase of S-nitrosylated proteins during physiological aging. In contrast, 
the age-mediated effect in APP/PS1 mice was taken as a pathological aging, 
assuming a further increase of S-nitrosylation upon cerebral deposition of Aβ. Venn 
diagrams for the age comparison showed 17 NOS2-dependent SNO proteins that 
significantly increased only in aged APP/PS1 mice (Figure 13A). On the genotype 
comparison in old mice, there were 6 overlap SNO proteins that increased in APP/PS1 
vs APP/PS1/NOS2-/- and APP/PS1 vs WT mice. Five of these SNO proteins were 
modified by NO in response to cerebral amyloidosis (Figure 13B). The results further 
revealed four overlapping proteins when corrected for age- and genotype-dependent 
effects: N-myc downstream-regulated gene 2 protein (DRG2), NADH:ubiquinone 
oxidoreductase Subunit AB1 (NDUFAB1), excitatory amino acid transporter 1 
(SLC1A3), and Inactive hydroxysteroid dehydrogenase-like protein 1 (HSDL1) (Figure 
13C). The list of NOS2-dependent SNO proteins that were upregulated by aging and 
/ or APP/PS1 genotype is shown in table 7. 
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Figure 13.  Venn diagram of synaptosomal proteome in mouse brain. (A) The diagrams 
show the S-nitrosylation proteins that were increased in age comparison. Age effect 
was determined comparing 12- and 3-month-old mice of all genotypes. Seventeen 
NOS2-dependent S-nitrosylation proteins were highly expressed in pathologic aging. 
(B) The diagrams show S-nitrosylation proteins that were increased when the different 
genotypes were compared in old mice. Five NOS2-dependent S-nitrosylation proteins 
were increased in aged APP/PS1 mice. (C) The overlap results in increased NOS2-
dependent S-nitrosylation proteins from age (17 proteins) and genotype effects (5 
proteins) in APP/PS1 mice. There were four overlapping proteins between age and 
genotype comparison, NDRG2, NDUFAB1, SLC1A3, and HSDL1. Wild type (WT), 
NOS2-/-, APP/PS1 and APP/PS1/NOS2-/-.  
 
 
In comparison, twenty SNO proteins were found to be decreased exclusively 
on the age comparison (12- vs 3-month-old) of the APP/PS1 groups (Figure 14A). On 
the genotype comparison in old mice, there were 7 overlap SNO proteins that 
decreased in both analyses, APP/PS1 vs APP/PS1/NOS2-/- and APP/PS1 vs WT 
mice. Of which 6 SNO proteins were decreased due to the effect of APP/PS1 on WT 
  55 
and NOS2-/- mice (Figure 14B). The results showed no overlapping proteins from age 
and genotype effects (Figure 14C).  
 
 
Figure 14.  Venn diagram of synaptosomal proteome in mouse brain. (A) The diagrams 
show the S-nitrosylation proteins that were decreased in age comparison of mice 
samples. Age effect was determined by comparing 12- and 3-month-old mice in all 
genotypes. Twenty NOS2-dependent S-nitrosylation proteins were decreased in 
pathologic aging. (B) The diagrams show S-nitrosylation proteins that were decreased 
when the different genotypes were compared in old mice. 6 NOS2-dependent S-
nitrosylation proteins were decreased in aged APP/PS1 mice. (C) There was no 
overlap in decreased NOS2-dependent S-nitrosylation proteins from age and 
genotype effects in APP/PS1 mice. Wild type (WT), NOS2-/-, APP/PS1  and 
APP/PS1/NOS2-/- . 
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The functional classification of synaptosomal S-nitrosylated proteins that 
differentially regulated by age and genotype effects in mouse brain 
The selected significant proteins were chosen for further analysis. Table 7 
consists of 17 NOS2-dependent S-nitrosylation proteins that increased in 12-month vs 
3-month-old APP/PS1 mice (age effect) and 5 proteins that were increased in 12-
month-old APP/PS1 mice (genotype effect), as shown in figure 13. Table 8 consists of 
20 NOS2-dependent S-nitrosylation proteins that decreased in age comparison of 
APP/PS1 mice (age effect) and 6 proteins that were decreased in 12-month-old 
APP/PS1 mice (genotype effect), as shown in figure 14. To further understand the role 
of NOS2 in the selected proteins, all differentially regulated proteins (increased and 
decreased) were analyzed using Uniprot/SwissProt database and Panther GO 
database (http://pantherdb.org) “PANTHER version 13.1 Released 2017-04” at P < 
0.05 (Figure 15) (Thomas et al., 2003) according to their biological process and 
molecular function. 
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Protein Name 
Swiss-
Prot ID 
Gene Peptide Sequence 
SNO Pos. 
(aa) 
Factor 
Fold 
Change 
Bootstrap 
95% CI 
p-value 
Limma 
p-value 
RP 
Elongation factor 2 P58252 EEF2 STLTDSLVCK 41 Aging 1.2 yes 0.25 0.52 
Heme oxygenase 2 O70252 HMOX2 
GTLGGSNCPFQTTVAV
LR 
281# Aging 1.2 yes 0.35 0.34 
Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondria 
Q8K2B3 SDHA AAFGLSEAGFNTACLTK 89 Aging 1.2 yes 0.19 0.38 
Excitatory amino acid 
transporter 1 
P56564 SLC1A3 CLEENNGVDKR 375# 
Aging 1.2 yes 0.25 0.37 
APP/PS1 - WT 1.2 yes 0.99 0.73 
APP/PS1 - ANO 1.3 yes 0.72 0.45 
Phospholipid 
phosphohydrolase 3 
Q99JY8 PLPP3 GFYCNDESIK 68# Aging 1.3 yes 0.18 0.35 
Zinc transporter 3 P97441 SLC30A3 LEGMAFHHCHK 55# Aging 1.3 yes 0.30 0.46 
CLIP-associating protein 2 Q8BRT1 CLASP2 
SLLVAGAAQYDCFFQHL
R 
135# Aging 1.3 yes 0.40 0.58 
Succinyl-CoA ligase [ADP-
forming] subunit beta, 
mitochondrial 
Q9Z2I9 SUCLA2 ICNQVLVCER 152 or 158 Aging 1.3 yes 0.06 0.38 
Acyl carrier protein, 
mitochondrial 
Q9CR21 NDUFAB1 LMCPQEIVDYIADK 140 
Aging 1.4 yes 0.19 0.59 
APP/PS1 - WT 1.2 yes 0.99 0.73 
APP/PS1 - ANO 1.2 yes 0.91 0.69 
Acyl carrier protein, 
mitochondrial 
Q9CR21 NDUFAB1 LMCPQEIVDYIADKK 140 Aging 1.3 yes 0.29 0.54 
Sodium/potassium-
transporting ATPase subunit 
alpha-3 
Q6PIC6 ATP1A3 SSHTWVALSHIAGLCNR 418 Aging 1.3 yes 0.41 0.27 
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Inactive hydroxysteroid 
dehydrogenase-like protein 1 
Q8BTX9 HSDL1 CPWLAPSPR 265# 
Aging 1.3 yes 0.18 0.34 
APP/PS1 - WT 1.2 yes 0.99 0.73 
APP/PS1 - ANO 1.4 yes 0.72 0.45 
Succinyl-CoA:3-ketoacid 
coenzyme A transferase 1, 
mitochondrial 
Q9D0K2 OXCT1 STGCDFAVSPN 504 Aging 1.3 yes 0.13 0.22 
Receptor-type tyrosine-
protein phosphatase alpha 
P18052 PTPRA TGTFCALSTVLER 770# Aging 1.4 yes 0.19 0.48 
NFU1 iron-sulfur cluster 
scaffold homolog, 
mitochondrial 
Q9QZ23 NFU1 LQGSCTSCPSSIITLK 210 or 213# Aging 1.4 yes 0.05 0.38 
Protein NDRG2 Q9QYG0 NDRG2 
CPVMLVVGDQAPHEDA
VVECNSK 
255 and 274 
Aging 1.5 yes 0.23 0.38 
APP/PS1 - WT 1.3 yes 0.99 0.73 
APP/PS1 - ANO 1.2 yes 0.91 0.74 
AP-2 complex subunit beta Q9DBG3 AP2B1 ECHLNADTVSSK 857 Aging 1.7 yes 0.08 0.42 
Pyruvate carboxylase, 
mitochondrial 
Q05920 PC FLYECPWR 622 Aging 1.7 yes 0.03 0.03 
Alcohol dehydrogenase 
class-3 
P28474 ADH5 FCLNPK 103 
APP/PS1 - WT 1.4 yes 0.99 0.73 
APP/PS1 - ANO 1.6 yes 0.72 0.69 
 
Table 7. List of NOS2-dependent synapto-S-nitrosylation proteins increased by aging and / or APP/PS1 genotype. Positions of the 
SNO site refer to the canonic Swiss-Prot sequences. “Factor” describes the comparison by which the respective protein was identified, 
either based on aging or APP/PS1 genotype (NOS2-dependent). Proteins were selected based on statistical significance (either 
adjusted p-value < 0.05 (Limma or RankProduct) (Schwammle et al., 2013) or it lays on 95% confidence interval of bootstrap analysis) 
(Efron and Tibshirani, 1993), the magnitude of the response to 1.2 fold or higher (log2  ± 0.263), and the reproducibility among 
replicates (>50%). Hash sign (#) represents proteins which have not been reported in previous nitrosylation studies (Lee et al., 2012b).  
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Protein Name 
Swiss-
Prot ID 
Gene Peptide Sequence 
SNO Pos. 
(aa) 
Factor 
Fold 
Change 
Bootstrap 
95% CI 
p-value 
Limma 
p-value 
RP 
Alpha-internexin P46660 INA SFGSEHYLCSASSYR 10 Aging 2.0 yes 0.17 0.44 
Spectrin beta chain, non-
erythrocytic 1 Q62261 SPTBN1 
VAHMEFCYQELCQLAA
ER 
619 and 624 Aging 
1.7 
no 
0.09 0.05 
Myosin-10 Q61879 MYH10 ADFCIIHYAGK 576 Aging 1.6 yes 0.05 0.37 
Apoptosis-inducing factor 1, 
mitochondrial Q9Z0X1 AIFM1 
SNIWVAGDAACFYDIK 440 Aging 
1.4 
yes 
0.27 0.51 
Tyrosine-protein phosphatase 
non-receptor type substrate 1 P97797 SIRPA 
VICEVAHITLDR 229 Aging 
1.4 
yes 
0.09 0.23 
Neuronal growth regulator 1 Q80Z24 NEGR1 CEGAGVPPPAFEWYK 239 Aging 1.4 yes 0.05 0.37 
Mitochondrial import receptor 
subunit TOM40 homolog Q9QYA2 TOMM40 
FLCGFGLTIG 354 Aging 
1.4 
yes 
0.25 0.19 
Cell adhesion molecule 3 Q99N28 CADM3 LLLHCEGR 252 Aging 1.3 yes 0.10 0.38 
Peptidyl-prolyl cis-trans 
isomerase FKBP1A P26883 FKBP1A 
RGQTCVVHYTGMLEDG
K 
23 Aging 
1.3 
yes 
0.31 0.41 
AP-2 complex subunit alpha-2 P17427 AP2A2 FHLCSVPTR 532 Aging 1.3 yes 0.10 0.26 
Cell adhesion molecule 2 Q8BLQ9 CADM2 SSPVMEGDLMQLTCK 146 Aging 1.3 yes 0.10 0.22 
Intercellular adhesion 
molecule 5 
Q60625 ICAM5 
MVTISCWAGAR 344 
Aging 
1.3 yes 0.13 0.41 
SWTWPEGPEQTLHCEA
R 
431 
1.2 
yes 
0.34 0.47 
LFSCEVDGKPEPR 595 1.2 yes 0.21 0.26 
AP-2 complex subunit alpha-1 P17426 AP2A1 FHLCSVATR 533 Aging 1.3 yes 0.14 0.28 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 9, 
mitochondrial Q9DC69 NDUFA9 
CDVYDIMHLR 86 Aging 
1.2 
yes 
0.31 0.51 
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Neuronal-specific septin-3 Q9Z1S5 SEPT3 VHCCLYFISPTGH 173 or 174 Aging 1.2 yes 0.18 0.23 
Guanine nucleotide-binding 
protein G(I)/G(S)/G(T) subunit 
beta-1 P62874 GNB1 
ELAGHTGYLSCCR 148 or 149 Aging 
1.2 
yes 
0.10 0.35 
Aminopeptidase B Q8VCT3 RNPEP GYCFVSYLAH 419 Aging 1.2 yes 0.29 0.53 
Guanine nucleotide-binding 
protein subunit beta-5 P62881 GNB5 
YYPSGDAFASGSDDAT
CR 
305 Aging 
1.2 
yes 
0.21 0.46 
Protein SOGA3 Q6NZL0 SOGA3 CQLQFVK 525 Aging 1.2 yes 0.28 0.36 
UPF0554 protein C2orf43 
homolog Q8BVA5 LDAH 
TDGWCPVK 275 Aging 
1.2 
yes 
0.25 0.59 
Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial 
Q9D051 PDHB EGIECEVINLR 263 
APP/PS1 - WT 1.2 yes 0.99 0.74 
APP/PS1 - ANO 
1.6 
yes 
0.60 0.61 
Clathrin heavy chain 1 Q68FD5 CLTC 
HSSLAGCQIINYR 151 APP/PS1 - WT 1.4 yes 0.83 0.73 
MEGNAEESTLFCF 217 
APP/PS1 - WT 1.2 yes 0.99 0.73 
APP/PS1 - ANO 1.3 yes 0.72 0.68 
YESLELCR 436 APP/PS1 - ANO 1.4 yes 0.15 0.23 
Fascin Q61553 FSCN1 NASCYFDIEWCDR 334 
APP/PS1 - WT 1.4 yes 0.99 0.78 
APP/PS1 - ANO 1.4 yes 0.73 0.68 
Synaptotagmin-1 P46096 SYT1 
LGDICFSLR 
 
277 
APP/PS1 - WT 1.2 yes 0.99 0.73 
APP/PS1 - ANO 1.3 yes 0.60 0.66 
ATP synthase subunit epsilon, 
mitochondrial P56382 ATP5E 
FSQICAK 19 
APP/PS1 - WT 1.3 yes 0.99 0.74 
APP/PS1 - ANO 1.3 yes 0.73 0.80 
Glyoxalase domain-containing 
protein 4 Q9CPV4 GLOD4 
ALLGYADNQCK 
 
182 APP/PS1 - WT 
1.2 
yes 
0.99 0.73 
HEEFEEGCK 41 APP/PS1 - ANO 1.3 yes 0.72 0.51 
 
Table 8. List of NOS2-dependent synapto-S-nitrosylation proteins that decreased by aging and / or APP/PS1 genotype. Positions of 
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the SNO site refer to the canonic Swiss-Prot sequences. “Factor” describes the comparison by which the protein was identified, either 
based on aging or APP/PS1 genotype (NOS2-dependent). Proteins were selected based on the statistical significance (either 
adjusted p-value < 0.05 (Limma or RankProduct) (Schwammle et al., 2013) or it lays on 95% confidence interval of bootstrap analysis) 
(Efron and Tibshirani, 1993), the magnitude of the response  to 1.2 fold or higher (log2  ± 0.263), and the reproducibility among 
replicates (>50%). Hash sign (#) represents proteins which have not been reported in previous nitrosylation studies (Lee et al., 2012b).
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The analysis of the involved biological processes of the 18 NOS2-dependent 
SNO proteins (Table 7) that increased by age and genotype comparisons revealed a 
contribution to the following mechanisms/pathways: metabolic processes (34.4%), 
cellular processes (28.1%), biological regulation (12.5%), response to stimulus 
(12.5%), localization (9.4%), and multicellular organismal processes (3.1%). However, 
the biological process of 26 decreased NOS2-dependent SNO proteins (table 8) 
includes more variances such as cellular process (27.5%), localization (22.5%), 
cellular component organization or biogenesis (12.5%), metabolic process (12.5%), 
developmental process (5%), multicellular organismal process (7.5%), biological 
regulation (5%), immune system process (2.5%), biological adhesion (2.5%) and 
locomotion (2.5%). Metabolic process and cellular processes were two of the highest 
percentage within the biological process category. 
 
Next, the classification was done for all of the differentially regulated SNO 
proteins from age- and genotype-dependent manner on their molecular function. The 
increased proteins on both comparisons were classified into: catalytic activity (57.2%), 
binding (14.3%), transporter activity (14.3%), translation regulator activity (7.1%) and 
structural molecule activity (7.1%). Additionnally the molecular function of the 26 SNO 
proteins that decreased was involved in: catalytic activity (46.6%), binding (40%), 
transporter activity (6.7%) and structural molecule activity (6.7%). 
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Figure 15. Pie chart showing the functional classification of increased and 
decreased synaptosomal SNO proteins in both age- and genotype-dependent 
manner of mouse samples. The iodoTMT identified changes in the synaptosomal 
proteome were characterized using gene ontology (GO) analysis. Functional 
categories were based on the annotations of GO using the PANTHER classification 
system for the categories of biological process and molecular function.  
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3.8.2. Synaptosomal S-nitrosylated Proteins in AD. 
Pairwise comparisons of protein regulation were performed between samples 
from AD, MCI and healthy controls (Table 1). The pairwise comparisons were done 
based on the AD stage and healthy control status. Volcano plots on figure 16 show S-
nitrosylation proteins with replicate numbers > 50% that were differentially regulated 
in AD disease progression (control to MCI, MCI to AD or control to AD).  
The candidate proteins in figure 16 were shown in different colors. The most 
substantial candidates will be from red points, which indicate candidates with p-value 
< 0.05 (Limma or RankProduct) (Schwammle et al., 2013), within 95% confidence 
iInterval of bootstrap analysis (Efron and Tibshirani, 1993) and have a fold change of 
≥ 1.2 fold (log2  ± 0.263). The green points indicate candidates with p-value < 0.05, 
not within 95% confidence interval of bootstrap analysis and have a fold change of ≥ 
1.2 fold (log2  ± 0.263). The blue points indicate candidates with p-value > 0.05, within 
95% confidence interval of bootstrap analysis and have a fold change of ≥ 1.2 fold 
(log2  ± 0.263). While the gray points indicate candidates with p-value > 0.05, not 
within 95% confidence interval of bootstrap analysis and have a fold change of < 1.2 
fold (log2  ± 0.263). Selected proteins for further analysis were chosen from red, green 
and blue points. 
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Figure 16. Volcano plot of synaptosome proteome displaying S-nitrosylation proteins 
from the human samples that were increased during AD disease progression. (A) MCI-
Control. (B) AD-MCI. (C) AD-Control. Negative log2 p-values (adjusted) were plotted 
against log2 protein fold change. Increased protein levels were shown on the positive 
x-axis, and decreased levels were shown on the negative x-axis. The red points show 
candidates with p-value < 0.05 (Limma or RankProduct) (Schwammle et al., 2013), 
within 95% confidence interval of bootstrap analysis (Efron and Tibshirani, 1993) and 
have a fold change of ≥ 1.2 fold (log2  ± 0.263). The green points show candidates 
with p-value < 0.05, not within 95% confidence interval of bootstrap analysis and have 
a fold change of ≥ 1.2 fold (log2  ± 0.263). The blue points show candidates with p-
value > 0.05, within 95% confidence interval of bootstrap analysis and have a fold 
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change of ≥ 1.2 fold (log2  ± 0.263). The gray points show candidates with p-value > 
0.05, not within 95% confidence interval of bootstrap analysis and have a fold change 
of < 1.2 fold (log2  ± 0.263). 
 
 
Applying the same reproducibility among replicates (>50%), statistical analysis 
(either adjusted p-value < 0.05 (Schwammle et al., 2013) or it lays on 95% confidence 
interval of bootstrap analysis (Efron and Tibshirani, 1993) and the magnitude of the 
response (FC 1.2-fold or higher) for human candidates as for mouse group 
proteins/peptides, only 1 SNO proteins was found elevated in MCI compared to control 
samples, 16 SNO proteins were increased on AD compared to MCI, and 9 SNO 
proteins were increased on AD compared to control (Figure 17A). No protein/peptide 
was found to be overlap in regulation between all three pairwise comparisons. Myelin-
oligodendrocyte glycoprotein (MOG), glutathione s-transferase Mu 3 (GSTM3) and 
four and a half LIM domains protein 1 (FHL1) were found increased in two pairwise 
comparison groups (AD vs MCI and AD vs Control). In parallel, 1 SNO proteins was 
decreased in MCI compared to control samples, 9 SNO proteins were decreased on 
AD compared to MCI, and 2 SNO proteins were decreased on AD compared to control. 
No overlap proteins/peptides were found between three pairwise comparison groups 
(Figure 17B). 
 
 
Figure 17. Venn diagram of synaptosomal proteome in human brain. Proteins were 
selected based on the statistical significance (either adjusted p-value < 0.05 
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(Schwammle et al., 2013) or it lays on 95% confidence interval of bootstrap analysis 
(Efron and Tibshirani, 1993) and the reproducibility among replicates (>50%). A) The 
venn diagrams show S-nitrosylation proteins that were increased during AD disease 
progression (MCI-Control; AD-MCI; AD-Control) with the magnitude of the response 
to 1.2-fold or higher (log2  ± 0.263). MOG, GSTM3 and FHL1 were the proteins with 
fold change values of 1.2-fold or higher (log2  ± 0.263) in two pairwise comparison 
groups (AD vs MCI and AD vs Control). B) The venn diagrams show S-nitrosylation 
proteins that were decreased during AD disease progression (MCI-Control; AD-MCI; 
AD-Control) with the magnitude of the response to 1.2-fold or higher (log2  ± 0.263). 
There is no overlap between pairwise comparison groups. 
 
 
The functional classification of synaptosomal S-nitrosylated proteins that 
differentially regulated by AD stage in human brain 
Table 9 provides the list of twenty-three NOS2-dependent S-nitrosylation 
proteins, which were significantly increased during AD disease progression. While 
table 10 consists of twelve NOS2-dependent S-nitrosylation proteins, which were 
significantly decreased in AD disease progression. The selected increased or 
decreased proteins were then classified using Uniprot/SwissProt database and 
Panther GO database (http://pantherdb.org) “PANTHER version 13.1 Released 2017-
04” at P < 0.05 (Figure 18) (Thomas et al., 2003) according to their biological process 
and molecular function.
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Protein Name 
Swiss-
Prot ID 
Gene Peptide Sequence SNO Pos. (aa) Factor 
Fold 
Change 
Bootstrap 
95% CI 
p-value 
Limma 
p-value 
RP 
Four and a half LIM domains 
protein 1 
Q13642 FHL1 FWHDTCFR 65# 
AD - MCI 1.4 no 0.09 0.05 
AD - Control 1.4 yes 0.20 0.30 
Glutathione S-transferase Mu 3 P21266 GSTM3 SCESSMVLGYWDIR 3 
AD - MCI 1.4 yes 0.23 0.13 
AD - Control 1.4 yes 0.40 0.55 
Myelin-oligodendrocyte 
glycoprotein 
Q16653 MOG 
FSDEGGFTCFF 127# AD - MCI 1.3 yes 0.42 0.45 
ALVGDEVELPCR 53# AD - Control 1.2 yes 0.68 0.58 
Neurocan core protein O14594 NCAN YQCNEGFAQHHVATIR 1244
# MCI - Control 1.8 yes 0.57 0.63 
Ankyrin-2 Q01484 ANK2 FWLIDCR 1304# AD – MCI 1.6 yes 0.09 0.15 
Brain-specific angiogenesis 
inhibitor 1-associated protein 2  Q9UQB8 BAIAP2 FCFLVEK 
195# AD – MCI 
1.4 
yes 
0.21 0.30 
Calcium/calmodulin-dependent 
protein kinase type II subunit 
gamma Q13555 CAMK2G WLNVHYHCSGAPAAPL 
549# AD – MCI 
1.6 
yes 
0.09 0.35 
2',3'-cyclic-nucleotide 3'-
phosphodiesterase 
P09543 CNP 
RPPGVLHCTTK 252# 
AD – MCI 
1.6 yes 0.19 0.18 
LDEDLAAYCR 111# 1.4 yes 0.30 0.22 
Cysteine and glycine-rich 
protein 1 
P21291 CSRP1 
TVYFAEEVQCEGNSFHK 25 
AD – MCI 
1.5 yes 0.09 0.00 
SCFLCMVCK 34 and 37 1.3 yes 0.18 0.30 
Band 4,1-like protein 1 Q9H4G0 EPB41L1 DYFGLTFCDADSQK 143# AD – MCI 1.2 yes 0.22 0.36 
Glucose-6-phosphate 
isomerase  
P06744 GPI MIPCDFLIPVQTQHPIR 404 AD – MCI 1.4 yes 0.60 0.39 
Hyaluronan and proteoglycan 
link protein 2  Q9GZV7 HAPLN2 
LTLSEAHAACR 265
# AD – MCI 
1.6 
yes 
0.19 0.13 
Kelch repeat and BTB domain-
containing protein 11 O94819 KBTBD11 
GDAAVYCFHAAAGEWR 329
# AD – MCI 
1.3 
yes 
0.14 0.26 
P62937 PPIA IIPGFMCQGGDFTR 62# AD – MCI 1.3 yes 0.25 0.19 
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Peptidyl-prolyl cis-trans 
isomerase A KITIADCGQLE 
161# 
1.2 
yes 
0.25 0.16 
26S proteasome non-ATPase 
regulatory subunit 6 Q15008 PSMD6 QYLFSLYECR 
266# AD – MCI 
1.2 
yes 
0.28 0.32 
Prostaglandin E synthase 3 Q15185 PTGES3 HLNEIDLFHCIDPNDSK 58 AD – MCI 1.4 yes 0.09 0.27 
Versican core protein P13611 VCAN 
NGFDQCDYGWLSDASVR 294# 
AD – MCI 
1.5 yes 0.21 0.32 
FDAYCFKPK 345# 1.5 yes 0.16 0.22 
CD44 antigen P16070 CD44 ALSIGFETCR 77# AD – Control 1.5 yes 0.29 0.30 
Actin, cytoplasmic 1 P60709 ACTB DDDIAALVVDNGSGMCK 17 AD – Control 1.3 yes 0.20 0.22 
Choline transporter-like protein 
2 Q8IWA5 SLC44A2 CQFAFYGGESGYHR 
427# AD – Control 
1.3 
yes 
0.58 0.50 
Myelin proteolipid protein P60201 PLP1 VCGSNLLSICK 220 and 228# AD – Control 1.3 yes 0.62 0.58 
Cathepsin B 
P07858 CTSB 
DQGSCGSCWAFGAVEAI
SDR 
105 and 108 AD - Control 
1.3 
yes 
0.61 0.51 
Aspartate aminotransferase, 
cytoplasmic P17174 GOT1 TDDCHPWVLPVVK 
70 AD - Control 
1.2 
yes 
0.62 0.55 
 
Table 9. List of twenty-three NOS2-dependent synapto-SNO proteins that were increased during AD disease progression in human 
samples. Positions of the SNO site refer to the canonic Swiss-Prot sequences. “Factor” describes the comparison in which the protein 
was identified based on the disease progression. Proteins were selected based on the statistical significance (either adjusted p-value 
< 0.05 (Limma or RankProduct) (Schwammle et al., 2013) or it lays on 95% confidence interval of bootstrap analysis) (Efron and 
Tibshirani, 1993), the magnitude of the response to 1.2 fold or higher (log2  ± 0.263), and the reproducibility among replicates (>50%). 
Hash sign (#) represents proteins which have not been reported in previous nitrosylation studies (Lee et al., 2012b).  
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Protein Name 
Swiss-
Prot ID 
Gene Peptide Sequence 
SNO Pos. 
(aa) 
Factor 
Fold 
Change 
Bootstrap 
95% CI 
p-value 
Limma 
p-value 
RP 
Neurofilament light polypeptide P07196 NEFL TLEIEACR 322
# MCI - Control 2.0 yes 0.57 0.64 
Aconitate hydratase, mitochondrial 
Q99798 ACO2 
DLGGIVLANACGPCIGQW
DR 
448 and 451 AD - MCI 
1.2 
yes 
0.36 0.41 
60 kDa heat shock protein, 
mitochondrial P10809 HSPD1 AAVEEGIVLGGGCALLR 
442 AD – MCI 
1.3 
yes 
0.09 0.15 
Isoleucine--tRNA ligase, mitochondrial Q9NSE4 IARS2 RPYWCISR 521# AD – MCI 1.3 yes 0.23 0.17 
Malate dehydrogenase, mitochondrial P40926 MDH2 SQETECTYFSTPLLLGK 285 AD – MCI 1.3 yes 0.27 0.33 
Neuronal cell adhesion molecule Q92823 NRCAM 
AAPYWITAPQNLVLSPGE
DGTLICR 
382# AD - MCI 
1.2 
yes 
0.52 0.40 
Pyruvate dehydrogenase E1 
component subunit alpha, somatic form, 
mitochondrial 
P08559 PDHA1 
LPCIFICENNR 218 and 222# AD – MCI 1.2 yes 0.09 0.01 
VDGMDILCVR 
261# AD – MCI 
1.3 
yes 
0.06 0.01 
Plexin-A1 Q9UIW2 PLXNA1 FECGWCVAER 828 and 831# AD – MCI 1.4 no 0.06 0.01 
Mitochondrial-processing peptidase 
subunit beta O75439 PMPCB FHFGDSLCTHK 
265# AD – MCI 
1.4 
no 
0.09 0.01 
Mitochondrial glutamate carrier 1 Q9H936 SLC25A22 VYTSMSDCLIK 52# AD – MCI 1.3 yes 0.09 0.08 
Rabphilin-3A (Exophilin-1) Q9Y2J0 RPH3A KNFNICLER 515# AD - Control 1.4 yes 0.29 0.31 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 8 P51970 NDUFA8 CALDFFR 
66# AD - Control 1.2 yes 
0.20 0.22 
 
Table 10. List of twelve NOS2-dependent SNO proteins that were decreased during AD disease progression in human synaptosome 
samples. Positions of the SNO site refer to the canonic Swiss-Prot sequences. “Factor” describes the comparison in which the protein 
was identified based on disease progression. Proteins were selected based on the statistical significance (either adjusted p-value < 
0.05 (Limma or RankProduct) (Schwammle et al., 2013) or it lays on 95% confidence interval of bootstrap analysis) (Efron and 
Tibshirani, 1993), the magnitude of the response to 1.2 fold or higher (log2  ± 0.263), and the reproducibility among replicates (>50%). 
Hash sign (#) represents proteins which have not been reported in previous nitrosylation studies (Lee et al., 2012b).  
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In the analysis of the human samples, the biological process of 23 
NOS2-dependent SNO proteins, which were increased by AD disease 
progression increased SNO proteins (Table 9) includes biological regulation 
(8.3%), cellular component organization or biogenesis (13.9%), cellular process 
(27.8%), developmental process (11%), Immune system process (5.6%), 
localization (2.8%), metabolic process (13.9%), multicellular organismal 
process (13.9%), and response to stimulus (2.8%). While the biological process 
of decreased NOS2-dependent SNO proteins (Table 10) consist of more 
variances such as metabolic process (29.1%), cellular process (25%), 
localization (12.4%), cellular component organization or biogenesis (8.3%), 
developmental process (4.2%), multicellular organismal process (4.2%), 
biological regulation (4.2%), biological adhesion (4.2%), locomotion (4.2%) and 
response to stimulus (4.2%). Metabolic process and cellular processes were 
also two of the highest percentage from the biological process category. 
 
Next, the classification was done for all of the differentially regulated 
SNO proteins in human samples with respect to their molecular function. The 
increased proteins were classified into: catalytic activity (30.7%), binding 
(23.1%), structural molecule activity (23.1%), receptor activity (7.7%), signal 
transducer activity (7.7%) and transporter activity (7.7%). While the molecular 
function of 12 SNO proteins that decreased in human samples was involved in 
catalytic activity (50%), binding (20%), transporter activity (10%) and receptor 
activity (10%) and signal transducer activity (10%). 
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Figure 18. Pie chart showing the functional classification of increased and 
decreased synaptosomal SNO proteins in human samples. The iodoTMT 
identified changes in the synaptosomal proteome were characterized using 
gene ontology (GO) analysis. Functional categories were based on the 
annotations of GO using the PANTHER Classification System for the 
categories of Biological process and molecular function.  
 
 
To see test whether there is a correlation between mouse and human 
data sets, a direct comparison of mouse and human SNO proteins was 
performed. Selected candidate proteins (increased or decreased) from the 
murine synaptosome samples were matched with human candidate proteins. 
Proteins from table 7 were compared to table 9 and proteins list in table 8 to 
table 10. This study did not reveal any overlap of increased or decreased SNO 
proteins (or peptides) between murine and human data sets. 
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4. Discussion 
4.1. Overview of the study 
The aim of this study is to identify new biomarker candidates for 
neuroinflammation in progression to MCI and AD. To achieve this, proteomic 
analysis was implemented using the iodoTMT enrichment procedure and 
coupled with HPLC-MS/MS, to identify synaptosomal s-nitrosylated proteins or 
peptides that are modified in a NOS2-dependent manner in murine and human 
samples.  
 
Detailed descriptions of the methodological workflow are given in figure 
19, from sample generation to protein/peptide identification and quantitation 
using an isobaric tag labeling procedure and nanoHPLC-MS/MS. In general, 
synaptosome isolation was done by sucrose density gradient followed by 
labeling and enrichment procedure using the iodoTMT method, along with 
mass spectrometry analysis.  
 
For the analysis of s-nitrosylation of proteins and peptides, pairwise 
comparisons were calculated to test the effect of: (1) age on each genotype 
and (2) APP/PS1+/- and NOS2-/- at different ages. While in human analysis, 
pairwise comparisons were created to investigate changes along AD 
progression by comparing brain samples derived from patients with a diagnosis 
of AD compared to MCI and aged-matched healthy individuals. 
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Figure 19. Schematic image of the isobaric tag labeling procedure (Wijasa et 
al., 2017). Reproduced from “Proteome profiling of s-nitrosylated synaptosomal 
proteins by isobaric mass tags”, by T. S. W ijasa et al., 2017, Journal of 
Neuroscience Methods, 291, p. 95-100. Copyright 2017 by Elsevier B. V. 
 
 
4.2. Synaptosome proteomic 
Density-gradient centrifugation techniques are used for synaptosome 
preparation. These are similar to the isolation of other subcellular fractions 
containing relatively pure cellular organelles such as the differential 
centrifugation of sucrose (Gray and Whittaker, 1962; Whittaker et al., 1964), 
Percoll (Nagy and Delgado-Escuata, 1984) or Ficoll/sucrose (Booth and Clark, 
1978). All techniques include steps to purify crude synaptosomal fractions from 
their contaminants such as nuclei etc. The exact reagents used for the 
formation of the density gradient and for buffering may differ from lab to lab 
however, depending on specific applications or personal preferences. As an 
example, the protocol used by the Henekalab (sucrose density gradient) is 
described for routine preparation of synaptosomes from fresh human or mouse 
brain tissue. The purity of the isolated synaptosomes can be analyzed 
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biochemically with enzymatic markers or estimated by morphological means 
using electron microscopy. Sucrose density gradient is easy to adapt and does 
not require specialized tools. It is also evenly applicable for both murine and 
postmortem human tissue. 
 
 Comprehensive studies on the synaptic proteome have been performed 
in the past (Bai and Witzmann, 2007; Chang et al., 2013; Engmann et al., 2010; 
Zareba-Koziol et al., 2014). There are various technical approaches used in 
proteomics for SNO protein quantification such as gel-based, mass spec-
based, stable-isotopic labels, or label-free; each has its own unique advantages 
and deficiencies. Therefore, the suitability of a chosen technique can affect the 
outcome of a study and experimental design must therefore be done with great 
care. 
 
 
4.3. Experimental design 
To prevent protein degradation when in isolated form, harvested murine 
brains were stored immediately in liquid nitrogen and afterwards put at −80°C 
for longer storage. Sample handling was performed at −4°C. Human brain 
samples were obtained with maximum PMI of 4 hours from Banner Sun Health 
Research Institute (BSHRI) Brain and Body Donation Program in Sun City, 
Arizona, based on the NIA-Reagan Criteria for the Postmortem Diagnosis of 
AD.  
 
To achieve an optimal result, a combination of fractionation (liquid 
chromatography) and protein enrichment (iodoTMT labeling) was used on an 
MS-based method. In HPLC-MS-based proteomics, complex mixtures of 
proteins are enzymatically cleaved into peptides and subsequently analyzed by 
mass spectrometry, this is also called bottom-up proteomics (Zhang et al., 
2013). Processed proteomic data sets contain thousands of data points, each 
consisting of peptide MS/MS spectra and m/z values, which consist of amino 
acid sequence information. Peptide identification is carried out by comparing 
observed tandem mass spectra from peptide fragmentation with theoretical 
spectra from a protein database. Peptides can be uniquely matched to a single 
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protein or shared by more than one protein. Nevertheless, because of post-
translational modification, all peptides referring to the same protein will not 
exhibit the same behavior.  
 
The iodoTMT approach gave an extensive amount of identified proteins 
acquired from a low amount of starting material (as low as 50 μg of protein from 
synaptosome lysate) – an important notion for disease-related studies that 
frequently have to deal with limited amounts of primary material such as 
synaptosome proteins. Though only cysteine-containing proteins were 
analyzed, more than a thousand proteins were identified by HPLC-MS/MS. In 
comparison to prior published studies, the total number of identified SNO 
proteins was equal or higher (Engmann et al., 2010; Zareba-Koziol et al., 2014). 
The approach used in this study is able to identify low abundant endogenous 
levels of SNO proteins without prior induction of nitrosylation by NO donor 
treatment. Furthermore, it is easy to adapt for human and murine samples.  
 
Mouse data analysis was done to evaluate age- and genotype-mediated 
effects. It has been shown previously that aging is highly influential in 
neurodegenerative diseases such as AD (Rizza et al., 2018; Wyss-Coray, 
2016; Zareba-Koziol et al., 2014)(Rizza et al., 2018; Wyss-Coray, 2016; 
Zareba-Koziol et al., 2014). Being a non-modifiable factor of cognitive decline 
and AD (Spaan, 2016), aging influences the increase or decrease of SNO 
protein levels. To identify the differences in SNO protein levels, 12-month old 
mice were compared to 3-month-old mice in all four mice genotypes. The age 
effect of WT animals was set as a control, showing an increase of S-nitrosylated 
proteins during physiological aging. The age-mediated effect detected in 
APP/PS1 mice interpreted as pathological aging, assuming a further increase 
of S-nitrosylation upon cerebral deposition of Aβ. Additionally, to identify NOS2-
dependent SNO proteins modifications during aging, the same statistical 
analysis was repeated by comparing the SNO proteome of old and young mice 
of NOS2-/- and APP/PS1/NOS2-/- background. The present study showed that 
age contributes to differentially regulated levels of nitrosylated proteins in all 
four genotypes mice. It also showed that physiological aging itself may 
contribute to the increase and decrease of nitrosylated proteins. 
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As for the genotype effect in old mice, WT was compared to NOS2-/- in 
order to identify the effect of NOS2 gene deletion in WT animals. APP/PS1 mice 
were compared to APP/PS1/NOS2-/- to identify the effect of NOS2 gene 
deletion on the APP/PS1 background. Furthermore, APP/PS1 was compared 
to WT to identify the effect of APP/PS1 vs WT control. The SNO proteins that 
were differentially regulated in mouse and human samples were then used for 
GO analysis to identify the biological process and molecular function (both 
increased and decreased proteins). Beyond our expectation, the volcano plot 
for APP/PS1 vs WT control is quite flat compared to WT vs NOS2-/- and 
APP/PS1 vs APP/PS1/NOS2-/- mice. Comparing the significant SNO 
proteins/peptides of APP/PS1 vs WT control on age- and genotype-
comparisons, age appears to have more influence in AD mouse model rather 
than genotype. To maximize the results, this study combined the data from age- 
and genotype-comparisons. In an ideal result, the significant NOS2-dependent 
proteins identified in age-mediated effects would overlap 100% with the 
genotype-mediated effects. When the two are compared however, the number 
of overlapping proteins was found to be low in increased proteins (see fig. 13c) 
and none in decreased proteins (see fig. 14c). This is potentially caused by 
missing values as peptides can be present in a sample but at a concentration 
below the detection limit of the mass spectrometer. Alternatively, a peptide can 
be present in a sample at a level above the detection limit but fail to be identified 
due to technical issues with sample processing or preparation. As such future 
studies may find more overlapping proteins.   
 
 
4.4. Statistical analysis of quantitative proteomics data 
One of the problems of quantitative analyses in proteomics is multiple 
non-identical data sets due to missing values (Nilsson et al., 2010; Schwammle 
et al., 2013). In order to perform optimal statistical analysis, the combination of 
Limma, RankProduct and bootstrap analysis was utilized. Limma and bootstrap 
analysis have been used before for quantitative proteomics to detect fold 
differences in complex samples (Gamazon et al., 2018; Jeannin et al., 2018; 
Mateus et al., 2018) and also in the isobaric labeling approach to identify PTM 
  78 
proteins (Zhang et al., 2016a). While Schwammle et al. has recommended the 
combined use of Limma and RankProduct, which is suitable for large 
quantitative data sets with missing values from mass spectrometry experiments 
(Schwammle et al., 2013). 
 
Limma and RankProduct are well-established methods for statistical 
analysis of large data sets with missing values and are reliable to maintain the 
correct estimation of type I error (false positive) (Mukherjee et al., 2003; 
Schwammle et al., 2013). While the bootstrap method provides a more 
accurate family wise error rate (FWER) (probability of making false discovery 
or type 1 error) and introduces fewer false negatives (type 2 errors) than 
standard methods (e.g., Bonferroni's correction) for multiple comparison 
analyses (Dudoit et al., 2004; Forrest et al., 2005; Søgaard et al., 2014). Their 
combined use is complementary and yields high detection numbers of 
regulated features (du Prel et al., 2009). 
 
From the initial analyses, despite having high fold change, not all 
peptides passed the p-value cutoff of < 0.05 using Limma and RankProduct. 
This indicates that tests will classify a peptide/protein as non-significant, though 
it lies within the 95% bootstrap confidence interval. Bootstrap analysis 
generated a higher number of significant peptides/proteins compared to Limma 
and RankProduct. It is necessary however to evaluate both p-value and fold 
change when selecting candidate proteins/peptides. Thus, a non-significant 
protein with high fold change and within the confidence interval was considered 
as an interesting candidate.  
 
Furthermore, to assure the quality of the results, exclusion criteria were 
used to select candidate proteins/peptides. This involved the exclusion of 
peptides that occur only one or two replicates, that had a Pearson correlation 
score of 0.5 (moderate correlation) on the internal standard and peptides 
detected in less than 50% of the whole sample set. After applying the statistical 
analysis, increased or decreased SNO proteins/peptides were identified in 
mouse and human synaptosomal samples. 
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4.5. General analysis of the synapto-SNO proteins 
Differential expression of SNO proteins can be caused by changes in 
protein expression (up or down) before nitrosylation (Hong et al., 2009; Papuc ́ 
et al., 2015), changes in NOS2 expression induced by neuroinflammation (only 
increased) (Chen et al., 2012; Heneka et al., 2015) and other sources of 
reactive NO species such as oxidative stress due to aging, environmental 
toxins or lifestyle factors (Ahmad, 1995; Al-Gubory, 2014; Faraco et al., 2014; 
Nakamura et al., 2013). 
 
Despite the hypothesis that the amount of nitrosylated proteins/peptides 
would increase in the murine AD model, proteins/peptides with a decreased 
number of nitrosylated cysteine residues were identified. The decrease of SNO 
proteins/peptides potentially results from the identification of proteins/peptides 
that are continuously nitrosylated under physiological conditions but with lower 
expression in AD related samples (Gould et al., 2013). It may also suggest that 
expression of the three NOS enzymes, that are capable of generating the NO 
needed for such modifications, include non-established patterns; i.e. 
constitutive NOS isoforms (NOS1, NOS3) are expressed when induced and 
NOS2 is constitutively expressed (Mattila and Thomas, 2014; Nakamura and 
Lipton, 2016). 
 
In general, the highest percentage of SNO proteins/peptides are 
involved in metabolic and cellular processes. This result is in line with previous 
works showing alterations of metabolic pathways in AD, which may exacerbate 
neurological symptoms (Cai et al., 2012; Kaddurah-Daouk et al., 2013; 
Trushina et al., 2013). The next highest percentage of biological process 
classifications is cellular process, this includes regulation of cell growth, cell 
cycle, cell division, cell communication and cell death. To identify synapto-SNO 
proteins/peptides that might be associated with inflammation-induced NOS2 
activation, the search was then focused on the up-regulated/increased S-
nitrosylated proteins/peptides in mouse and human synaptosomal samples. 
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4.6. S-nitrosylated proteins analysis in mouse synaptosome samples on 
age and genotype effects 
Mouse data was evaluated for age- and genotype-mediated effects. 
Young (3-month-old) and old mice (12-month-old) were used in the present 
study to identify age-dependent effects on each genotype. Aging is a complex 
process that depends on many factors including genetic, epigenetic and 
environmental factors throughout life. It is the biggest risk factor for cognitive 
decline and AD and is a non-modifiable factor (Sochocka et al., 2017; Spaan, 
2016). Importantly, this study found that SNO proteins/peptides are regulated 
(up- or down-regulated) during physiological aging (Nakamura et al., 2013).  
 
NOS2-/- mouse data was used to investigate the role of NOS2-derived 
NO during the inflammatory response observed in AD neuroinflammation 
(Colton et al., 2006; Fenyk-Melody et al., 1998). Therefore APP/PS1+/- were 
crossed with NOS2-/- animals. Based on previous SNO-proteome analysis, it 
was hypothesized that SNO proteins/peptides would decrease in aged 
APP/PS1 mice carrying a NOS2 gene deletion (Bateman et al., 2015; Colton et 
al., 2008; Kummer et al., 2012; Wilcock et al., 2008). Along with the increase of 
SNO proteins/peptides in human AD samples, this would suggest an early 
synaptic vulnerability for NO-mediated neuroinflammation (Heneka et al., 2015; 
Seneviratne et al., 2016). The non-overlapping synapto-SNO proteins of 
APP/PS1 samples were postulated to show NOS2-dependent proteins in the 
murine AD model. 
 
The overlapping proteins from the mouse study, according to age and 
genotype effects, included NDRG2, NDUFAB1, SLC1A3, and HSDL1 (figure 
13C) and were associated with AD previously (Bateman et al., 2015; Breuer et 
al., 2013; Kanehisa et al., 2016; Rong et al., 2017; Scott et al., 2002). NDRG2, 
HSDL1 and ADH5 proteins were associated with pathological aging. NDRG2 is 
a cytoplasmic protein involved in cell differentiation and mainly expressed in 
astrocytes in the CNS (Breuer et al., 2013). NDRG2 was found increased in 
aging APP/PS1 mice (Rong et al., 2017) and in the cortical neurons of late-
onset AD brains (mRNA and protein levels) when compared to controls; beyond 
age or gender effects (Mitchelmore et al., 2004). The NDRG2 gene is 
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expressed in the cerebral cortex (frontal, temporal, occipital lobes), cerebellum 
and hippocampus, which is known to be vulnerable to AD pathology 
(Mitchelmore et al., 2004; Rong et al., 2017). A recent study by Rong et al. 
showed the relationship between NDRG2 and AD pathology at the molecular 
level, mainly beta-amyloid accumulation and abnormal tau phosphorylation 
(Rong et al., 2017). Their study showed changes in NDRG2 might be related to 
the generation of beta-amyloid. It was also demonstrated that tau 
phosphorylation was increased in NDRG2 overexpressed cells and decreased 
in NDRG2 knock-down cells (Rong et al., 2017). Moreover, nitrosylated NDRG2 
has been identified previously to be involved in AD pathology (Seneviratne et 
al., 2016). HSDL1 is a mitochondrial protein that has been shown to mediate 
immune system processes, cell differentiation, homeostatic processes and 
system development (Bateman et al., 2015). No known studies have yet directly 
related HSDL1 to AD or found in nitrosylated form.  ADH5 is a mitochondrial 
protein that is associated with oxidoreductase activity, nitrosylation (Bateman 
et al., 2015; Breuer et al., 2013) and is differentially expressed in the 
hippocampus of AD patients (Guebel and Torres, 2016; Zhang et al., 2015).  
 
Interestingly, data retrieved from the KEGG pathway analysis shows 
NDUFAB1 (subunit complex I of the mitochondrial respiratory chain) and SDHA 
(subunit complex II of the mitochondrial respiratory chain) are associated with 
neurodegenerative disease including AD, Parkinson’s and Huntington’s 
disease (Breuer et al., 2013; Kanehisa et al., 2016). NDUFAB1 is essential for 
energy metabolism as it is a subunit from the first enzyme of the mitochondrial 
respiratory chain (Sharma et al., 2009). Deficiency of complex I is frequently 
found in various tissues of patients with neurodegenerative disease such as AD 
(Kim et al., 2001; Wang et al., 2017). NDUFAB1 has been shown to be 
responsible for oxidative phosphorylation and downregulated in AD patients 
(Akila Parvathy Dharshini, 2018; Kim et al., 2001). NDUFAB1 reduction may 
lead to energy metabolism impairment and result in neuronal cell death 
(apoptosis) (Kim et al., 2001).  
 
While SDHA is essential for the generation of ATP (oxidative 
phosphorylation) and involved in the nervous system development (Breuer et 
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al., 2013; Grimm, 2013). Oxidative stress induces the increase of SDHA 
expression in the brain of AD patients (Bubber et al., 2005; Shi and Gibson, 
2011). This study identified both proteins as NOS2-dependent SNO modified 
proteins that increased during aging in APP/PS1 mice. Nitrosylated NDUFAB1 
protein has been reported to be increased in Parkinson’s disease samples 
(mouse and human) (Hsu et al., 2005). Increase level of nitrosylated SDHA was 
found in the ovine mitochondrial of heart failure compare to control samples 
(Radcliffe et al., 2017). Though nitrosylated SDHA has been identified before, 
there are not many articles published in relation to AD. Thus, nitrosylated 
NDUFAB1 and SDHA may be of interest for mechanistic studies and as 
potential biomarker candidates. 
 
Other interesting proteins were SLC1A3, SLC30A3 and EEF2, which are 
synapse-related proteins (Bateman et al., 2015; Breuer et al., 2013). SLC1A3 
or also known as Excitatory amino Acid Transporter 1 (EEAT1) plays an 
important role in chemical transmission and glutamate secretion (Bateman et 
al., 2015). Recently SLC1A3 has been identified to be nitrosylated in AD 
(Seneviratne et al., 2016). SLC1A3 is a glutamate transporter that is expressed 
in astrocytes and microglia (Ong et al., 2013; Scott et al., 2002). Aβ impaired 
glutamate uptake causes glutamate accumulation in the extrasynaptic spaces, 
resulting in synaptic dysfunction via posttranslational modifications such as 
nitrosylation (Nakamura et al., 2013; Tu et al., 2014). SLC30A3 (Zinc 
transporter 3 or ZnT3) is a synaptic protein that is involved in neuronal zinc 
transport to the synaptic cleft (Bateman et al., 2015; Cole et al., 1999). 
SLC30A3 protein has been related to amyloid beta synaptic targeting 
(Deshpande et al., 2009) and found reduced in the prefrontal cortex of AD 
patients (Beyer et al., 2009; Kurita et al., 2016) and an AD mouse model 
(Tg2576 mice) (Lee et al., 2012a). Although previous studies showed a 
decrease of SLC30A3 levels, this study identified for the first time a significant 
increase in nitrosylated SLC30A3 during the progression of pathology in the AD 
mouse model investigated. The elevated proportion of nitrosylated SLC30A3 
may be caused by an increased NO level of the protein (nitrosylation process) 
due to inflammation.  
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EEF2 is a main regulator for protein synthesis (initiation, elongation, and 
termination), synaptic plasticity, memory and consolidation (Li et al., 2005; 
Taha et al., 2013). EEF2 protein level is reduced in frontal cortex of AD brain 
samples (Garcia-Esparcia et al., 2017; Li et al., 2005) and APP/PS2 transgenic 
mice (Garcia-Esparcia et al., 2017). Increase phosphorylated EEF2 has been 
linked to AD pathogenesis (Argüelles et al., 2014; Li et al., 2005) and is 
considered a potential AD biomarker (Henriques et al., 2016). EEF2 
phosphorylation prevents it from binding to the ribosome (inactivation), thus 
decreasing the rate of peptide elongation and protein synthesis (Argüelles et 
al., 2014). Increased nitrosylated EEF2 has been identified in the 
synaptosomes of APP transgenic mice compared to wild type (Zareba-Koziol 
et al., 2014). Our study shows that NOS2-dependent nitrosylated EEF2 is 
increased in aged APP/PS2 transgenic mice compared to young. Identical 
peptide sequence (STLTDSLVCK) was found, which is in line with the result 
from Zareba-Koziol et al.  
 
 
4.7. S-nitrosylated proteins analysis in human synaptosome samples 
Although no overlap protein/peptide was found in all three pairwise 
comparisons of human samples, three synapto-SNO proteins (MOG, FHL1 and 
GSTM3) were found overlapping during AD disease progression (AD vs MCI 
and AD vs Control). MOG and FHL2 proteins were identified as nitrosylated for 
the first time. MOG was identified both in human and mouse results (12-month-
old APP/PS1 compared to 12-month-old APP/PS1/NOS2-/- mice). MOG is a 
component in the central nervous system myelin, which is expressed at the 
oligodendrocyte plasma membrane and outer surface of the myelin sheath 
(Bateman et al., 2015; Brunner et al., 1989). Increased MOG has been shown 
as one of the early biomarkers for memory loss in AD using serum samples 
(Papuc ́ et al., 2015) and CSF of AD patients, which indicates altered immune 
system activity (Maetzler et al., 2011). It has also been used as a biomarker for 
multiple sclerosis diagnosis (Olsen et al., 2016). MOG can prevent axonal 
regeneration and trigger demyelinating autoimmunity through T cell-mediated 
autoimmune response (Ohtani et al., 2011; Podbielska et al., 2013). 
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FHL1 is a truncated form of complement factor H and mainly expressed 
in the cardiac and skeletal muscle (Hellwage et al., 1997; Lee et al., 1998). 
FHL1 gene mutation results in various chronic myopathies including rigid spine 
syndrome (RSS), scapuloperoneal (SP) and Emery-Dreifuss muscular 
dystrophy, which are characterized by an increased accumulation of 
aggregated proteins and vacuoles with misfolded proteins (Sabatelli et al., 
2014). FHL1 protein plays a role in inflammatory reactions by enhancing the 
phagocytosis of Aβ (Hellwage et al., 1997). Increased expression of FHL1 was 
found in AD brain homogenates (Strohmeyer et al., 2002). GSTM3 belongs to 
the glutathione S-transferase (GST) superfamily and acts as a protective 
enzyme from oxidative stress (Tchaikovskaya et al., 2005). Oxidative stress is 
increased in the aging brain and appears to contribute to AD pathogenesis 
(Huang et al., 2016). GSTM3 staining was observed at sites of Aβ deposition, 
neurofibrillary tangles and in microglia of AD brains (Hong et al., 2009; Maes et 
al., 2010; Tchaikovskaya et al., 2005) and was also found to be nitrosylated 
before (Lee et al., 2012b). 
 
Further interesting proteins that were found to be nitrosylated for the first 
time include PLP1, CAMKI2G, PPIA and CD44. PLP1 (or myelin proteolipid 
protein) is a major myelin protein of the CNS, which is also involved in 
inflammatory responses and synaptic transmission (Bateman et al., 2015). In 
AD frontal cortex samples, the MAG:PLP1 ratio (myelin associated glycoprotein 
to proteolipid protein 1 ratio) was significantly reduced (Thomas et al., 2015). 
The MAG:PLP1 ratio was used as an indicator for oxygenation to estimate 
possible hypoperfussion in AD (Miners et al., 2016). Calcium/calmodulin-
dependent protein kinase type II subunit gamma (CAMK2G) is known to have 
an important role for nervous system development, memory formation and 
synaptic plasticity (Bateman et al., 2015). CAMK2 is found to be dysregulated 
in AD cases, and may directly contribute to synaptic degeneration and memory 
deficits (Ghosh and Giese, 2015). PPIA (peptidyl-prolyl cis-trans isomerase A, 
also known as CyPA or Cyclophilin A) is a secreted protein from monocytes 
(Nigro et al., 2013) that determines protein folding and trafficking (Bateman et 
al., 2015). The secretion of protein PPIA is increased during aging (Li et al., 
2011), inflammation (Nigro et al., 2013) and AD (Bell et al., 2012). CD44 is a 
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cell surface glycoprotein protein that is broadly expressed on immune cells 
(membranes of B cells, monocytes and mature T cells) and may act as an 
adhesion molecule for astrocyte (Akiyama et al., 1993; Wak and Saunders, 
2006). It is involved in the regulation of synaptic plasticity, neuronal 
development, neurodegeneration (AD, Parkinson, multiple sclerosis) and 
immune responses (Bateman et al., 2015; Dzwonek and Wilczynski, 2015; Wak 
and Saunders, 2006). CD44 expression is induced by the pro-inflammatory 
cytokine TNF (tumor necrosis factor) and is upregulated on T cells during an 
immune response (Baaten et al., 2010). The level of CD44 expression is 
elevated in astrocytes and lymphocytes of AD patients (Akiyama et al., 1993; 
Dzwonek and Wilczynski, 2015; Mossello et al., 2011). Increased CD44 
expression was also observed in the substantia nigra of human Parkinson 
brains and in astrocytes of Parkinson’s mouse model (Neal et al., 2018). 
Furthermore, CD44 expression is increased in the brains and spinal cords of 
EAE (experimental autoimmune encephalomyelitis) mouse model of multiple 
sclerosis (Guan et al., 2011). 
 
 
4.8. Variance of protein expression in murine and human samples 
In an ideal situation, the candidate protein/peptide should be able to 
characterize the disease with 100% sensitivity and 100% specificity. However 
in reality, identifying such protein biomarkers has proven to be very difficult. 
Utilizing the approach from this study, the number of significant SNO 
proteins/peptides found in human synaptosomes was lower compared to those 
derived from murine tissue. Human brain tissue samples are difficult for 
differential proteomics, e.g. due to variable post mortem intervals and 
preanalytical sample handling (before brain banking). The result of the present 
study could be influenced by both technical and biological differences.  
 
Technically, murine brain samples can be processed immediately after 
euthanizing the animal, which is not possible for human brain samples. 
Moreover, murine brain samples were cooled immediately by perfusion using 
cold saline solution. Previous studies have shown that controlled cold 
temperature can lower the activity of nitric oxide synthases in murine and 
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human samples, as this was demonstrated particularly for NOS2 (Hodges et 
al., 2006; Venturini et al., 1999). In contrast, there was a post mortem interval 
for human samples of up to 4 h. Loss of proteins (or nitrosylation of proteins) 
due to degradation during the postmortem period may have limited the yield of 
SNO proteins/peptides in human samples (Zareba-Koziol et al., 2014). In order 
to resolve this, a rapid autopsy program for AD patients, designed to analyze 
labile PTM within a four-hour post mortem interval is needed (i.e. Rapid Autopsy 
Program of the University Kentucky Alzheimer’s Disease Research Center, 
UKADRC) (Schmitt et al., 2012). The post-mortem interval and small amounts 
of biopsy tissue available for the human study, compromise equal comparative 
measurements with mice samples.  
 
Furthermore, synaptosomes from mouse brains could be prepared 
without freeze-thaw cycles, whereas human brain samples were acquired as 
frozen material from a biobank, which did not prepare its specimen specifically 
for this type of analysis. Potentially, the SNO proteome could be further 
preserved using appropriate inhibitors or chemical stabilizers in addition to 
cooling and protease inhibitors, when added instantly during preservation. 
Such substances have not found widespread use yet, despite some studies 
reporting use of such inhibitors already (Foster et al., 2012; Koo et al., 2016).  
 
Biologically, mouse genetic backgrounds and environmental factors 
were planned and controlled, while human factors are heterogeneous and 
cannot be completely controlled.  Lifestyle, disease states, environmental 
factors, age and genetic variation can also influence the physiological condition 
of human brains (Rescigno et al., 2017; Tripathy et al., 2011).  
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4.9. Challenges and limitations of this study 
A few challenges and limitations were encountered in this study. Though 
highly efficient, the whole workflow consists of multiple steps (such as blocking, 
labeling, enrichment, cleaning, digestion) that are time-consuming and may 
contribute to inter-run variances. When analyzing reporter ion intensities from 
the same to same-experiment through all identified peptides (all 6 labels), there 
was an average variance of 20% between single reporter ion channels and the 
mean of all channels, which were evaluated through all of the identified 
peptides. This score shows the method variance was within this range. 
Variance can be introduced at different stages of analysis, which includes 
manual preparative pipetting, sample preparation, digestion, IodoTMTTM 
labeling and enrichment until pooling and analysis of the samples.  
 
To control the variables in this quantitative study, it is best to set up an 
internal standard, which contains pooled and aliquoted proteins of all 
representative samples. The internal standard should be added at an early 
stage of each preparation batch and treated as one of the sixplex samples on 
each LC- MC-run. This allows to manage any technical errors or 
inconsistencies that may interfere with quantitation. Although this internal 
standard cannot diminish inter-run-variances, it could be used for quality control 
purposes. An internal standard was used throughout the experiment; it was 
labeled and measured in all runs with iodoTMT126 label reagent. It was 
expected that this sample would show high correlation between the different 
raw-files using Pearson correlation coefficient (Figure 10). Variation could be 
due to the stability of the iodoTMT labeling reagent after reconstitution, which 
found to be limited to 1 week when stored at -20 °C (Wijasa et al., 2017). 
Therefore, it is recommended to perform all labeling steps for a study within this 
time frame.  
 
A further limitation arises from the way of labeling and enrichment. Due 
to fact that only modified peptides are identified and quantified, the procedure 
generally depends on MS/MS-based information implied from a single peptide 
ion. Accordingly, protein identifications are only valid when originated from 
unique (protein-specific) modified peptides. If the identified peptides are not 
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unique, protein classes or multiple proteins have to be treated as a potential 
origin of the peptide. 
 
Another challenge is the statistical analysis. Proteomic detection 
experiments depend on quantitation at the MS/MS level but iodoTMT is known 
to undergo ratio compression (Bantscheff et al., 2007; Savitski et al., 2011) and 
hence will show smaller effects. As a result, the p-values will be higher, and the 
corrected p-values also increase, which lets less proteins/peptides pass the 
corrected thresholds (Pascovici et al., 2016). Despite having elevated the fold 
change, few of the proteins/peptides in this study did not pass the p-value 
cutoff. This suggests a peptide/protein be classified as non-significant by 
Limma and RankProduct analyses, though it lies in the 95% bootstrap 
confidence interval. Instead of focusing only on p-value to indicate the degree 
of confidence in a statistical conclusion, this study used both the p-value and 
the confidence interval. The p-values generated during hypothesis testing are 
dependent on the effect size (i.e. the difference between groups compared) 
meaning larger differences yield lower p-values (Pascovici et al., 2016). 
 
P-value alone does not inform the size or direction of a difference 
between different groups, while confidence interval does (Bland and Peacock, 
2002). P-value is considered clearer than confidence interval due to its rapid 
decision (yes-or-no) to decide if a value is statistically significant or not (du Prel 
et al., 2009). However, this “diagnosis on sight” can lead to misinterpretation, 
as it can lead to clinical decisions that only based on statistics. Confidence 
interval gives an estimated range of values, which is likely to contain population 
of interest (Morey et al., 2016). The confident interval is less inclined to 
misinterpretation and more informative than the p-value (Wood, 2005).  
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4.10. Conclusion 
In general, investigating S-nitrosylation of proteins/peptides prooved to 
be difficult due to S-nitrosothiol stability and the low abundance of SNO 
proteins/peptides (without NO donor treatment for s-nitrosylation). The low 
amount of synaptosomal material further complicated this work. This study 
does however provide a list of potential synaptosomal AD biomarker candidates 
of aberrant S-nitrosylation. For validation of the findings, each selected 
nitrosylated protein/peptide can be tested by targeted analysis to compare AD, 
MCI and control non-AD subjects. The results implicate that these candidate 
proteins/peptides could be beneficial as both early diagnostics and outcome 
measures; which needs to be confirmed in larger studies using CSF samples.  
 
There are numerous biomarker methods for AD discovery and 
identification, however there is no single biomarker for AD that can fulfill all the 
criteria for an ideal biomarker. Definite limitations such as sample handling and 
lack of method standardization exist for almost all current approaches. Next to 
this limitation, the application of a combination of biomarkers may be necessary 
to obtain an accurate and reliable identification of preclinical AD. Therefore, a 
combination of imaging, biochemical, genetic and cognitive assessments may 
be essential to achieve the best option for an AD biomarker. 
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Protocols (supplement) 
1. BCA protein assay 
1.1. Working solution (Thermo Scientific) 
Columns in well plate 4 6 8 12 
Stock A (clear white solution) 6.6 mL 10 mL 13 mL 20 mL 
Stock B (clear blue solution) 0.14 mL 0.2 mL 0.26 mL 0.4 mL 
 
1.2. BSA standard is prepared from 2mg/ml (vial), diluted with distilled 
water 
1.3. 96 well plate (in duplo, example: 1-2 and 3-4) 
 1 2 3 4 … 12 
A 25 μl WR 25 μl WR 2.5 μl sample 1 2.5 μl sample 1   
B 25 μl ampuwa 
/ 0 
25 μl 
ampuwa / 0 
2.5 μl sample 2 2.5 μl sample 2   
C 25 μl BSA 
62.5 μg/mL 
25 μl BSA 
62.5 μg/mL 
2.5 μl sample 3 2.5 μl sample 3   
D 25 μl BSA 
125 μg/mL 
25 μl BSA 
125 μg/mL 
2.5 μl sample 4 2.5 μl sample 4   
E 25 μl BSA 
250 μg/mL 
25 μl BSA 
250 μg/mL 
2.5 μl sample 5 2.5 μl sample 5   
F 25 μl BSA 
500 μg/mL 
25 μl BSA 
500 μg/mL 
2.5 μl sample 6 2.5 μl sample 6   
G 25 μl BSA 
1000 μg/mL 
25 μl BSA 
1000 μg/mL 
2.5 μl sample 7 2.5 μl sample 7   
H 25 μl BSA 
2000 μg/mL 
25 μl BSA 
2000 μg/mL 
2.5 μl sample 8 2.5 μl sample 8   
 
1.4. Add 200 μl of working solution to each well (A-H to 1-4) 
1.5. Incubate for 30 min to 1 hour (with lid on) at 37 °C -> color will change 
from clear green to clear purple) 
1.6. Read the absorbance at 562 nm against a reagent blank using a 
microplate reader (Beckman Coulter Co.). The samples concentration 
was measured with reference to standards. 
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2. Whole brain tissue homogenization 
2.1. Add 1 ml/ 150 mg tissue (wet weight) homogenization buffer + protease 
inhibitors.  
2.2. Homogenize tissue using Precellys 24 tissue homogenizer (Bertin 
technology) at 5500 rpm speed for 20 seconds. 
2.3. Aliquot in 200 µl fractions (H fraction) 
2.4. If it is needed, use one aliquot for RNA extraction, mix it with 1600μl 
Trizol 
2.5. Lyse 200 μl with an equal volume of RIPA buffer.  
2.6. Sonicate for 15 s, 80% duty, 12% power.  
2.7. Incubate for 30 min on ice. 
2.8. Centrifuge at 100000 g for 30 min in ultra centrifuge (TLA-55) at 4 °C 
2.9. Save supernatant (R fraction) and pellet (F fraction) in – 80 °C 
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